Choice of implant filler in breast reconstruction: A study of the cost-effectiveness of saline and silicone implants by Nelligan, Kathleen
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
11-27-2018 5:00 PM 
Choice of implant filler in breast reconstruction: A study of the 
cost-effectiveness of saline and silicone implants 
Kathleen Nelligan 
The University of Western Ontario 
Supervisor 
Doherty, Christopher 
The University of Western Ontario Co-Supervisor 
Sarma, Sisira 
The University of Western Ontario 
Graduate Program in Surgery 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Kathleen Nelligan 2018 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Plastic Surgery Commons 
Recommended Citation 
Nelligan, Kathleen, "Choice of implant filler in breast reconstruction: A study of the cost-effectiveness of 
saline and silicone implants" (2018). Electronic Thesis and Dissertation Repository. 5954. 
https://ir.lib.uwo.ca/etd/5954 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
 i 
Abstract 
 
Breast reconstruction following mastectomy is increasing and implant-based breast 
reconstruction is the most common surgical approach. Saline and silicone implants have 
different cost and complication profiles and it is unclear which is the more cost-effective 
option. A systematic review of the literature was undertaken to summarize the quality of 
life data in breast reconstruction, specifically, previously published health state utility 
values relevant to breast reconstruction. In addition, a cost-utility analysis was undertaken 
from the perspective of the third-party payer, accounting for the most common 
complications associated with saline and silicone implants. This demonstrated that 
despite the increased initial cost of silicone implants, they are cost-effective with a 
willingness-to-pay threshold of $50,000 (ICUR $52.26/QALY). Overall, silicone 
implants provide improved quality of life with a marginal cost increase.  
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Saline-filled implant, silicone implant, implant-based breast reconstruction, cost-utility 
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1. Chapter 1: Introduction 
 
Overview 
The purpose of this thesis is to compare silicone and saline implants in terms of cost-
effectiveness in the context of breast reconstruction. This chapter reviews the clinical 
context of increasing demand for reconstructive breast surgery and the available 
surgical options. In addition, a brief overview of the existing cost-effectiveness 
analyses in breast reconstruction will be undertaken, highlighting the gaps in the 
literature on comparison of implant types. Finally, the regulatory climate and the 
present challenges in health care spending and planning will provide a framework 
for the rationale for this project. 
 
1.1. Clinical Context: Breast Cancer and The Increasing Rate of Mastectomy 
Breast cancer is the most common cancer among Canadian women, affecting 1 in 8 
women over their lifetime.(1) Although breast cancer continues to represent 13 percent of 
cancer deaths among Canadian women, the mortality rate has declined over the past three 
decades likely due to the increased use of screening mammography and improved breast 
cancer treatments.(1,2)  
 
Treatment goals and pathways are dictated by the stage of breast cancer at the time of 
presentation and typically consist of surgical resection of the primary tumour with or 
without chemotherapy and radiation. Surgical ablation of the primary tumour can be in 
the form of either lumpectomy (i.e., breast conserving therapy) or mastectomy. In early 
stage breast cancer (Stage I or II), lumpectomy followed by radiation is comparable to 
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mastectomy in overall survival, although mastectomy is associated with a decreased rate 
of local recurrence.(3–5)  
 
Despite the more invasive nature of mastectomy, recent literature has shown that more 
women are choosing mastectomy over breast conserving therapy.(6) Prophylactic 
mastectomy is also increasing in frequency. Contralateral prophylactic mastectomy 
reduces the relative risk of contralateral breast cancer by 95 percent in women who have 
had breast cancer, reflecting an absolute risk reduction of approximately 20 to 25%.(7,8) 
From 1998 to 2003, rates of contralateral prophylactic mastectomy increased 
approximately 150 percent in women with invasive breast cancer.(9) The same trend has 
been identified among women with ductal carcinoma in situ.(10) In addition, with the 
widespread availability of testing for BRCA genetic mutations over the past two decades, 
bilateral prophylactic mastectomy as a risk reducing strategy is increasingly chosen.(11) 
The choice of mastectomy and or contralateral prophylactic mastectomy over breast 
conserving therapy or unilateral mastectomy alone is multifactorial; however, women 
who choose the former tend to be younger and of Caucasian race and to have private 
insurance coverage, larger tumours and family histories of breast or ovarian 
cancer.(6,8,9,12) The rationale behind the choice of surgical resection is incompletely 
understood; however, fear of developing a cancer in the contralateral breast in addition to 
the desire for a more symmetric reconstruction have been cited.(13) 
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1.2. Overview of Breast Reconstruction 
1.2.1. Need for Breast Reconstruction Surgery 
The combination of early detection, improved treatment and patient preference for 
mastectomy has contributed to a greater number of women surviving breast cancer with 
significant mastectomy defects. Breast scars and deformities due to mastectomy can 
decrease quality of life.(14–16) It is generally accepted that breast reconstruction 
improves body image in women after mastectomy although factors such as personality 
traits and body mass index may influence the degree of improvement in quality of 
life.(17,18) Nonetheless, although many factors influence a woman’s decision to undergo 
reconstructive breast surgery, it is likely that these elements have contributed to the 
increased demand for breast reconstruction in recent years.  
 
Breast reconstruction rates have increased in the past 20 years in both Canada and the 
United States.(19,20) This has paralleled an increase in the rate of contralateral 
prophylactic mastectomy since women undergoing bilateral mastectomies tend to have 
higher rates of reconstruction.(21) An analysis of the United States Nationwide Inpatient 
Sample between 1998 and 2008 revealed that 60 percent of women who had contralateral 
prophylactic mastectomies underwent reconstruction while 81 percent of women 
undergoing bilateral prophylactic mastectomy underwent immediate reconstruction.(21) 
Additionally, the rate of reconstruction among women who had contralateral prophylactic 
mastectomies rose by 3 percent per year during the study period. Not only have rates of 
breast reconstruction increased, but the rate of implant-based reconstruction has also 
increased by 11 percent per year from 1998 to 2008 in the United States.(19) 
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In Ontario, the breast reconstruction rate increased from 19.3 percent in 2002 to 27.9 
percent in 2008.(20)  Unfortunately, there remains a significant geographic disparity 
across the province in immediate breast reconstruction rates, which may be attributed to 
access to a plastic surgeon.(20) In 2016, in an effort to increase access to breast 
reconstruction, Cancer Care Ontario (CCO) recommended that all women undergoing 
mastectomy be offered a consultation with a plastic surgeon to discuss breast 
reconstruction.(22) In addition, dedicated hospital funding to support breast 
reconstruction has been available since 2016 when CCO designated breast reconstruction 
as a Quality-Based Procedure.(23) Although it is too early to assess the effects of these 
changes, it is reasonable to expect rates of breast reconstruction to increase as a result. 
 
1.2.2. Breast Reconstruction Options 
Multiple techniques for breast reconstruction have been developed over the years and can 
broadly be categorized into autologous breast reconstruction and implant-based 
reconstruction. Both autologous and implant-based reconstructions can be performed as 
immediate (i.e., completed at the same time as mastectomy) or delayed procedures. 
Timing is influenced by a number of factors including tumour stage at presentation, 
requirement for adjuvant treatment, plastic surgeon availability and patient preference. 
 
1.2.2.1. Autologous Reconstruction 
Autologous breast reconstruction involves use of a patient’s own tissues to reconstruct 
the breast mound. It is especially helpful for patients who have undergone radiation as 
implant-based reconstruction can be challenging in a radiated tissue bed.(24) Tissue can 
be harvested either regionally with pedicled flaps or from distant sites requiring 
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microvascular anastomosis at the recipient site. The abdomen is the most common donor 
site for autologous breast reconstruction because an adequate volume of tissue is typically 
available and is of similar skin colour and consistency to breast tissue. Further, for large 
pendulous breasts, abdominal tissue is easily molded to match the contralateral breast 
shape. The transverse rectus abdominis (TRAM) myocutaneous flap has been a 
workhorse flap for autologous breast reconstruction. It results in good quality tissue for 
reconstruction of the breast mound and has the benefit of reducing redundant abdominal 
tissue, if desired. However, it is associated with donor site morbidity in the form of 
abdominal bulging and hernias due to weakening of the abdominal wall 
musculature.(25,26) The deep inferior epigastric (DIEP) flap avoids the donor site 
morbidity of the TRAM flap by preserving the rectus abdominis muscle and as such does 
not result in abdominal wall weakness.(26) Conversely, it may increase the frequency of 
complications at the breast recipient site including fat necrosis and partial or complete 
flap loss.(27) Other common flaps include the pedicled latissimus dorsi flap, which may 
be considered in women without sufficient abdominal tissue for reconstruction.(28) It 
may be used alone or in conjunction with implant-based reconstruction. 
 
1.2.2.2. Implant-Based Reconstruction 
Although autologous breast reconstruction has been found to be more cost-effective than 
implant-based reconstruction,(29) not all patients desire or are candidates for autologous 
reconstruction due to body habitus or personal choice. Implant-based breast 
reconstruction utilizes a synthetic implant to reconstruct the breast mound and, as for 
autologous reconstruction, can be either immediate or delayed. For either, the 
reconstruction may be performed as a single-stage or two-stage procedure. In a single-
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stage procedure, the implant pocket is developed and a permanent implant is placed. A 
two-stage procedure involves the initial placement of a tissue expander which acts to 
stretch the skin and soft tissues to accommodate a permanent implant which is placed at a 
later surgery following several months of serial expansion. Breast implants available in 
North America must be approved by the Food and Drug Administration (FDA) in the 
United States or Health Canada in Canada. Implants can be categorized by their shape, 
texture and content.  
 
1.2.2.3. Types of Breast Implants 
Breast implants available in North America are made with two types of fillers: silicone 
and saline. Silicone gel breast implants were developed by Dow Corning in 1962.(30) 
The evolution of breast implants is complex and can be confusing because of the 
nomenclature of “generations” of implants which describe the various types. The first 
generation of breast implants was characterized by a thick outer shell, firm interior gel, 
anatomic shape and a Dacron patch which was sutured to the chest wall to keep the 
implant in position.(31) Beginning in 1970, these were replaced by the second generation 
of implants which featured a round shape, a smooth, thin outer shell and a less viscous 
gel filler. An initial positive experience with these implants was characterized by a more 
natural shape and feel.  However, longer term follow-up demonstrated gel “bleed” (i.e., 
slow passage of silicone gel through an intact outer shell) and, more importantly, an 
extremely high rate of implant rupture.(32) The third generation of implants attempted to 
resolve these issues with a more cohesive gel filler and a thicker, low-bleed shell. These 
implants, first introduced in 1982, also featured a textured surface option. The fourth 
generation of implants was first introduced in 1993 and featured a more strongly cohesive 
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gel filler within the same low-bleed shell of the third-generation devices but was 
developed under strict regulatory control by the FDA with the intention of eventual re-
introduction into the market.(33) The fifth generation of implants was first developed in 
1993 and was characterized by a highly cohesive, form-stable gel. Like the fourth-
generation implants, these are available in smooth and textured surfaces with the same 
low-bleed shell; however, these are also available as anatomic implants in addition to 
round varieties.(31,33,34) 
 
Saline implants were developed in the 1950s but early versions were limited by high rates 
of deflation.(33) Eventually these were popularized in North America during the 1990s 
when silicone implants were removed from the market due to safety concerns, which 
included implant rupture, an association with connective tissue diseases and increased 
risk of breast cancer.(35) After numerous studies concluded that the latter two concerns 
were invalid, silicone implants were reintroduced in both Canada and the United States 
following the standard premarket approval processes.(36,37) Saline implants continue to 
be used but have higher complications rates including visible rippling, firm consistency 
and greater potential for noticeable deflation and resultant re-operation.(38,39) 
Conversely, potential advantages of saline implants include an ability to fill to volumes 
larger than those offered with silicone implants, a lower cost and an alternative for 
women who have inherent concerns about silicone gel implants. 
 
The two principle classes of implant shape are round and anatomic (“tear drop”). The 
theoretical advantage of an anatomic implant is the creation of a more naturally shaped 
breast mound with decreased upper pole fullness relative to round implants. Importantly, 
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the extent to which an implant holds its shape under the influence of gravity is influenced 
by the filler. Therefore, anatomic implants with more highly cohesive gel filler tend to 
maintain their upper pole shape against gravity. A recent study demonstrated that in the 
breast reconstruction population, patients who received round implants were more likely 
to undergo revision symmetry procedures than those who received anatomic 
implants.(40) Despite this theoretical advantage, numerous other studies have been 
unable to demonstrate a difference in appearance or quality of life between anatomic and 
round implants.(34,41) Further, the use of anatomic implants can be complicated by 
implant malposition, such as implant malrotation, and require subsequent reoperation for 
correction.(31) 
 
Both saline and silicone implants in current use have silicone elastomer shells that vary in 
surface characteristics. Broadly, these surface qualities are characterized as “smooth” and 
“texturized,” although textured implants have variable surface morphology based on 
patented designs by device manufacturers. While all implants will result in capsule 
formation, capsular contracture is less common with textured implants. (42) The textured 
surface is particularly common in anatomically-shaped implants as the surface texture 
helps maintain the implant position within the implant cavity. However, there are some 
drawbacks to the textured surface, namely the evolving body of literature suggesting an 
association with breast implant-associated anaplastic large cell lymphoma (BIA-
ALCL).(43,44) While the understanding of this disease is still developing and the 
reported incidence is low, rates reported in the literature are rising.(45) Rates of BIA-
ALCL may rise over the coming years with increased awareness and surveillance. 
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1.2.3. Summary of Clinical Problem 
Saline and silicone-filled implants are used in both the breast augmentation and 
reconstruction populations with good results. While silicone implants have been 
associated with higher rates of capsular contracture,(46) they have also been associated 
with improved patient satisfaction compared to patients with saline implants.(47) In 
Canada, the cost of silicone implants may be twice the price of saline implants.(30) Since 
satisfaction and rates of complications requiring reoperation differ between patients with 
saline versus silicone implants, it would be useful to determine the option that is most 
effective taking into account clinical outcomes, quality of life and cost. 
 
1.3. Economic Context: Decision-Making in a Publicly-Funded Health Care System 
In Canada, health care spending is among the highest internationally and is on the 
rise.(48) In 2015, health expenditure reflected 10.4 percent of the gross domestic product 
(GDP) and is expected to rise to 11.5 percent in 2017.(48) In a resource-constrained 
system, it is important to consider the value for money achieved with health care 
expenditures since spending in one area removes resources in other areas.  
 
Economic analyses are decision-making tools used to inform choice and funding of 
therapies or interventions with the goal of choosing the most economically effective 
options.(49) There are multiple forms of economic analysis, differentiated by the number 
and unit of measure of health outcomes (Table 1.1). Cost-minimization analysis compares 
cost when patient outcomes are equal. Cost-benefit analysis examines the monetary value 
of multiple patient outcomes. However, it is often challenging to assess the value of a 
health state in monetary terms. Cost-effectiveness analysis measures cost against a single 
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health outcome measured in natural units (e.g., life years gained). While this is a useful 
method of analysis, it can be challenging to compare analyses measured in different 
natural units (e.g., life years gained versus premature births avoided). Cost-utility analysis 
measures patient outcomes using a common denominator: healthy years (e.g., quality 
adjusted life years).(49)  
 
Table 1.1 Economic Analyses 
Method Assumption Number of Outcomes Unit of Outcome 
Cost-minimization analysis Patient outcomes equal None None 
Cost-benefit analysis Patient outcomes not equal Many Monetary 
Cost-effectiveness analysis Patient outcomes not equal One Natural Units 
Cost-utility analysis Patient outcomes not equal One Quality of Life 
 
 
1.3.1. Cost-Utility Analysis in Breast Reconstruction 
Cost-effectiveness analysis (CEA) is a type of economic evaluation that is used to 
determine the value for money of various treatments and interventions.(49) A subtype of 
CEA is cost-utility analysis (CUA), whereby cost is measured against health status, most 
commonly expressed in quality-adjusted life-years (QALYs).(50,51) The advantage of 
using a cost-utility analysis is that it facilitates comparisons of different interventions and 
health states through a common denominator, the QALY. Comparisons may be made 
across disease groups for which outcomes measured in natural units may not be directly 
comparable (e.g., hip fractures avoided versus life years gained).  
 
There are increasing numbers of cost-utility analyses examining breast reconstruction 
options. Several have compared autologous and implant-based reconstruction (29,52–54) 
Chapter 1 
 11 
while others have examined adjuncts to surgery and surgical materials such as CT 
angiography and acellular dermal matrix.(55,56) Overall, there is evidence to support 
greater cost-effectiveness with autologous reconstruction. Unfortunately, not all women 
are candidates for autologous reconstruction due to body habitus, comorbidities and 
patient preference. In terms of implant-based reconstruction, no cost-utility analysis has 
compared saline and silicone implants which are associated with different costs and 
quality of life. There is a clear clinical demand for implant-based breast reconstruction. 
However, given resource constraints, health care providers may be asked to justify use of 
devices seen as more costly. A cost-utility analysis of saline and silicone implants would 
provide helpful information to physicians, hospitals and policymakers when purchasing 
implants for breast reconstruction.  
 
A secondary consideration from the existing cost-utility analyses is choice of health state 
utilities. Often CUAs estimate new utility values for the health states included in the 
analysis. Although generating new health state utility values may allow for more accurate 
assessment of the specific health state description used in a model, repeatedly surveying 
physicians and patients is time-consuming and costly. Given the need for cost-
effectiveness analyses in resource-limited systems and the increasing rate of breast 
reconstruction, understanding the existing published health state utility values and the 
methods used to evaluate them is essential. Furthermore, developing strong estimates of 
health state utility values is paramount to enhancing the external validity of a CUA 
model.  
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1.4. Rationale for Cost-Utility Analysis in Implant-Based Breast Reconstruction 
Breast reconstruction is a recognized component of the cancer treatment pathway and 
rates are increasing in both the United States and Canada.(20) Further, implant-based 
reconstruction increased by 11 percent between 1998 to 2008 in the United States and 
continues to be the most common type of breast reconstruction in North America.(19) 
There is a clear clinical demand for implant-based breast reconstruction; however, there 
are a wide variety of implant designs to choose from with varying advantages and 
disadvantages. In a resource constrained health care system, whether publicly- or 
privately-funded, it is essential to consider the cost-effectiveness of these treatment 
options. An important element of implant-based breast reconstruction is implant choice. 
Saline and silicone implants have different quality of life, safety and cost profiles. It is 
essential to find cost-effective alternatives that continue to provide women seeking breast 
reconstruction a high quality of life in the survivorship period. Further, outlining the cost-
effectiveness of implant alternatives may help health care providers justify the use of 
interventions that are more costly but associated with improvements in quality of life. 
Therefore, the first component of this study is an examination of the existing health state 
utility values in breast reconstruction through a systematic review of the literature. The 
second component of this study is a cost-utility analysis of saline and silicone implants 
for immediate, unilateral, implant-based breast reconstruction. 
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2. Chapter 2: A Systematic Review of Utility Measurements in Breast Reconstruction 
 
Overview 
This chapter reviews approaches to health status assessment and utility generation. 
In addition, a systematic review of health state utility values in breast reconstruction 
explores the existing literature supporting this component of economic analysis in 
the breast reconstruction population. Utilities are summarized in a quantitative 
analysis and methods of health status assessment in this field are compared to 
existing guidelines. The results of this analysis can serve as a reference for utility 
values for future cost-utility analyses in breast reconstruction.1 
 
2.1. Introduction 
Breast reconstruction is an integral component of the breast cancer treatment pathway 
and rates are increasing in both the United States and Canada.(1,2) However, there are a 
wide variety of approaches ranging from autologous to implant-based options. Factors 
which may determine the best option for an individual woman include medical 
comorbidities, body habitus, breast cancer characteristics and personal preferences. 
Within these domains, there are a number of variables that can influence cost and quality 
of life associated with the procedure, including the use of venous couplers, acellular 
dermal matrices and implant type.(3–5) In a resource constrained health care system, it is 
essential to consider the cost-effectiveness of these and other treatment options. 
 
  
                                                        
1 A portion of the work covered in Chapter 1 is included here as part of the Integrated Article Format. 
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2.1.1. Cost-Utility Analysis 
Cost-effectiveness analysis (CEA) is a type of economic evaluation that is used to 
determine the value for money of treatments and interventions.(6) A subtype of CEA is 
cost-utility analysis (CUA), whereby cost is measured against health status, most 
commonly expressed in quality-adjusted life-years (QALYs).(7,8) The advantage of 
using a cost-utility analysis is that it facilitates comparisons of different interventions and 
health states through a common denominator, the QALY. This allows for comparisons 
across disease groups for which outcomes measured in natural units may not be directly 
comparable (e.g., hip fractures avoided versus life years gained). QALYs can be 
calculated by multiplying the value and duration of a given health state.(8) The value of a 
health state, known as the health state utility value (HSUV) or single index score, ranges 
from zero (death) to 1 (perfect health).(8) States worse than death can have a value less 
than zero. Thus, one QALY equates to one year of life lived in perfect health.  
 
!"#$ = &'() ∗ +,-./012	14	ℎ6.7/ℎ	8/./6	(:6.-8)  
1	!"#$ = 1 ∗ 1	:6.-  
 
2.1.2. Health Status Assessment 
Health state utility values can be generated through direct elicitation or indirect health 
status assessment.(9) Direct elicitation methods include techniques such as visual 
analogue scale (VAS), time trade-off (TTO) and standard gamble (SG) (Table 2.1).(8,9)  
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Table 2.1 Direct Elicitation Methods 
Method Description 
Visual Analogue Scale Respondents rank health states along a line with well-defined end points (e.g., 
perfect health and death) according to desirability. The utility of the impaired 
health state is the fractional distance along the continuous scale.(8) 
Time Trade-Off Respondents choose between two alternatives: living x years in an impaired 
health state or living in perfect health for y years (a shorter period of time). The 
time period is varied until respondent finds the two choices equivalent. Then the 
utility of the impaired health state is x/y.(9) 
Standard Gamble Respondents choose between remaining in an impaired health state or taking a 
gamble, in which they may return to full health or die. The probability of death is 
varied until the respondent finds the certainty and gamble equivalent. The utility 
of the impaired health state is the probability of returning to full health at the 
point of indifference.(9) 
 
 
When using a VAS, individuals are asked to rank health states along a scale from best to 
worst imaginable health or from perfect health to death.(8) Although attractive in its 
simplicity, this method is limited by inconsistent anchors, context bias (i.e., where 
valuation depends on number of states presented at the same time), scaling bias (i.e., 
reluctance to rate health states at extremes of the scale) and emphasis on rating rather 
than choice, which does not have grounding in economic theory.(8,10) Time trade-off 
and standard gamble both involve an element of choice and as such have stronger 
grounding in economic theory. The time trade-off method asks respondents to choose 
between living in an impaired health state for a period of time, x, and living in perfect 
health for a shorter period of time, y. The time of x or y is then varied until the respondent 
finds the choices equivalent. The utility is then y/x.(8,9) Standard gamble also presents a 
choice to respondents, asking them to choose between staying in a state of impaired 
health or taking a gamble in which they either return to full health or die. The probability 
of returning to full health is then varied until the respondent is indifferent at which point 
the probability is the utility of the impaired health state.(8,9) 
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Indirect health status assessment is performed through administration of questionnaires 
that address multiple domains of quality of life such as pain, physical functioning and 
emotional well-being.(8) Questionnaires can either be generic, assessing a broad scope of 
domains relevant to health in general, or specific to a given disease population.(9) 
Generic tools allow for comparison across multiple disease groups but can be insensitive 
to domains that are specific to particular disease populations.(11) For instance, breast 
reconstruction impacts multiple domains such as body image and sexual functioning, but 
these are not directly addressed in generic tools such as the Euro-Qol 5D (EQ-
5D).(12,13) However, condition-specific measures of quality of life decrease the 
comparability of results across diseases. Because of this, disease-specific measures must 
be mapped to a generic measure prior to being used in economic evaluations.(9) 
 
Health status questionnaires can be classified as either preference-based or non-
preference-based measures. Non-preference-based measures ask respondents to depict 
their health in different domains of quality of life and, in doing so, describe a health 
state.(14) Preference-based measures capture the desirability of a health state.(9) The 
latter, also referred to as multi-attribute utility scales, generate specific health states for 
which a single index score (i.e., health state utility value) is calculated using preference 
weights developed through direct elicitation surveys of the general population.(8) 
Importantly, preference-based questionnaires can be used to generate utilities. Scores 
from non-preference-based measures cannot be used directly to generate utilities; instead 
they must be mapped using a statistical function.(8) 
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Health state utility values (HSUVs) are commonly estimated by surveying patients, but 
they can also be assessed by surveying experts (e.g., physicians) or the general 
population. Importantly, each of these groups tend to value health states differently and 
there are limitations with surveying each of these populations. While the general 
population, comprised mainly of healthy individuals, tends to underestimate the utility of 
diseased health states, patients who have experienced those states and have become 
accustomed to them may place a higher value on those states.(9) Medical and surgical 
experts may have greater knowledge of diseased states than the general population but 
may be biased by their personal opinions of interventions and emotional connection with 
patients.(15) 
 
2.1.3. Existing CUAs in Breast Reconstruction 
There are increasing numbers of cost-utility analyses examining breast reconstruction 
options. Often these CUAs generate new utility values for the health states included in the 
analysis. Although generating new health state utility values may allow for more accurate 
assessment of the specific health state descriptions used in a model, repeatedly surveying 
physicians and patients is time-consuming and costly. Given the need for cost-
effectiveness analyses in resource limited systems and the increasing rate of breast 
reconstruction, understanding the existing published health state utility values and the 
methods used to evaluate them is essential. Furthermore, developing strong estimates of 
health state utility values is important to enhancing the external validity of CUA 
models.(16)  
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Thus, the purpose of this systematic review of utility measurements in breast 
reconstruction was twofold. The first aim was to describe the metrics used to generate 
utilities in the breast reconstruction literature and the second was to summarize the values 
reported for common early and late postoperative complications for implant-based and 
autologous breast reconstruction. 
 
2.2. Methods 
2.2.1. General 
A systematic review was conducted to identify previously reported utility values and 
quality of life outcomes generated through validated questionnaires in breast 
reconstruction for either therapeutic or prophylactic mastectomy. The main objective was 
to identify utility values for all health states relevant to breast reconstruction that can be 
used in future cost-utility analyses. 
 
2.2.2. Data Sources 
An electronic search of English-language literature was performed of MEDLINE® and 
Embase® databases for relevant articles published prior to November 2017. The search 
strategy was designed with assistance from a librarian experienced in systematic reviews 
(Table 2.2). In addition, reference lists of accepted papers and relevant review articles 
were manually reviewed to identify additional articles.  
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Table 2.2 Search Strategy 
No. Search 
1 exp mammaplasty/ or (mammaplast$ or mammoplast$ or mastoplast$).mp. or (breast$ adj5 
reconstruct$).mp. (16795) 
2 exp "Costs and Cost Analysis"/ (225003) 
3 (economic value of life or economics, medical or economics, pharmaceutical or models, economic 
or markov chains or monte carlo method or uncertainty).sh. (68649) 
4 economics.fs. (407092) 
5 (quality of life or quality-adjusted life years).sh. (180352) 
6 ((econom$ or cost or costly or costing or costed or prices or pricing or discount or discounts or 
discounted or discounting or budget$ or afford$ or pharmacoeconomic$ or pharmaco) adj1 
economic$).ti,ab. (228130) 
7 (decision adj1 (tree$ or analy$ or model$)).ti,ab. (15477) 
8 ((value or values or valuation) adj2 (money or monetary or life or lives)).ti,ab. (4665) 
9 (QOL or QOLY or QOLYs or HRQOL or QALY or QALYs).ti,ab. or (quality$ adj2 life$).tw. 
(243759) 
10 ((((quality adj1 life) or (willingness adj1 pay) or (quality adj1 adjusted life year$) or sensitivity) adj 
analys?s) or quality adjusted life expectanc$).ti,ab. (27847) 
11 economics.sh. (27494) 
12 (Economic Impact or Economic Value or Pharmacoeconomics or Health Care Cost or Economic 
Factors or Economics or Cost Analysis or Cost or Economic Analysis or Cost-Effectiveness or 
Costs or "Quality of Life" or Health Care Cost or Cost Savings or Cost-Benefit Analysis or Hospital 
Costs or Medical Costs or Quality-of-Life).mp. (892619) 
13 exp Economic Evaluation/ or exp Pharmacoeconomics/ or Quality Adjusted Life Year.sh. or exp 
Quality of Life/ (245192) 
14 or/2-13 (1285636) 
15 1 and 14 (1387) 
16 limit 15 to english language (1285) 
17 16 not (exp Animals/ not (Human/ and exp Animals/)) (1283) 
18 meta analysis.mp,pt. or MEDLINE.tw. or systematic review.tw. (256532) 
19 17 and 16 (1283) 
20 limit 17 to "review articles" (161) 
21 17 not 20 (1122) 
22 19 or 21 (1283) 
23 case report.ti. (213167) 
24 22 not 23 (1281) 
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2.2.3. Literature Screen 
After removal of duplicates, all citations were screened in two stages by two independent 
reviewers (Table 2.3). In the first stage, title and abstract were reviewed with the 
following exclusion criteria: abstract only, non-English language articles, case reports, 
letters, commentaries, non-systematic reviews, animal studies and in vitro studies. Since 
it was anticipated that there would be few reports of utility values and that this may be 
challenging to elicit from title and abstract alone, inclusion criteria were intentionally 
made broad for the first stage of screening. Articles were included if they met the 
following criteria: the study examined women undergoing breast reconstruction for either 
therapeutic or prophylactic mastectomy and the study had the potential to report utility 
values (i.e., was a possible economic analysis (i.e., referred to as cost-utility analysis, 
cost-analysis, economic analysis, cost effectiveness analysis in title or abstract), reported 
health state utility values (e.g., a report of independent utility generation, systematic 
review or meta-analysis of utilities) or reported on quality of life using a validated tool 
that could be used to generate utilities). If it was unclear whether a citation met the 
inclusion criteria based on title and abstract alone, it was included for full-text review. 
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Table 2.3 Systematic Review Inclusion and Exclusion Criteria 
 
Inclusion Criteria Exclusion Criteria 
First Stage Population 
• breast reconstruction for 
therapeutic or prophylactic 
mastectomy) 
Design 
• economic analysis 
• utility generation report or 
validated patient-reported 
outcome measure 
• systematic review/meta-
analysis 
Incorrect population 
Design 
• conference abstract 
• non-English language articles 
• case reports 
• letters 
• commentaries 
• non-systematic reviews 
• laboratory (animal or in vitro) 
studies 
Second Stage Design 
• cost-utility analysis 
• utility generation report 
Design 
• patient-reported outcome 
measure without utility values 
for specific postoperative health 
states 
 
 
In the second stage, the full text of articles that met inclusion criteria were reviewed in 
addition to those studies for which a determination could not be made based on title and 
abstract alone. A study was included after the second stage if it reported utilities (i.e. was 
a cost-utility analysis or if it generated or reported utility values without a formal 
economic analysis). Exclusion criteria at the second stage included incorrect study design 
(i.e. did not report utilities), with the addition of cost-analysis, cost-effectiveness analysis, 
cost-minimization analysis and cost-benefit analysis to the exclusion criteria. Studies that 
reported validated health status measures but did not report utility values for specific 
post-operative health states (e.g., complication states) were also excluded since the value 
reported was an aggregate of successful, unsuccessful and complicated procedures. 
 
2.2.4. Data Abstraction 
Data was abstracted from included studies encompassing the following details: author, 
journal, publication year, study design, study population (e.g., breast reconstruction, 
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implant-based breast reconstruction, autologous reconstruction etc.), intervention (e.g., 
subtype of implant-based or autologous reconstruction, use of acellular dermal matrix 
etc.), population and number of individuals surveyed to generate utility values, utility 
metrics, health states, health state definitions and utility values reported.  
 
2.2.5. Analysis 
Included studies were discussed in a narrative fashion. There is a lack of consensus on 
reporting methodology for HSUV studies; however, generic criteria have been published 
by Papaioannou et al. and used in other systematic reviews of HSUVs.(16,17) Others 
abide by the National Institute for Health and Clinical Excellence Guide to the Methods 
of Technology Appraisal or CHEERS reporting guidelines.(18,19) Study quality was 
described narratively with respect to these criteria. Studies that reported original utility 
values and the number of individuals surveyed for utility generation were included in a 
quantitative analysis in which weighted averages and standard deviations of reported 
values were calculated with weights based on number of individuals surveyed (Appendix 
1).(20) Since none of the articles reported confidence intervals or standard deviations for 
the health state utility values a formal meta-analysis could not be performed. All statistics 
were calculated using Microsoft® Excel®. 
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2.3. Results 
2.3.1. Search Results 
The systematic review process is outlined in the PRISMA flow chart (Figure 2.1). The 
literature search yielded 3060 records through MEDLINE and Embase of which 2279 
remained after duplicates were removed. In addition to 4 records identified through cross-
referencing, a total of 2283 records were screened. Of these, 2249 records were excluded 
based on title and abstract. Full-text review was done for 219 citations and 200 were 
excluded at this stage. Of the excluded citations, 17 were published in abstract format 
only, 9 were cost-analyses, 3 were not specific to breast reconstruction (i.e., were studies 
of women with breast cancer without specific assessment of reconstruction), 1 was a cost-
effectiveness analysis, 1 was a preference model that did not generate utilities and 169 
used non-preference-weighted quality of life measures. Of the full-text articles reviewed 
19 met inclusion criteria and only 10 of these published original utility values (i.e., not 
obtained from a synthesis of the literature) that could be incorporated into a pooled 
analysis. 
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Figure 2.1 PRISMA Search Strategy Flow Diagram Utilities 
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2.3.2. Study Design 
Of the articles included following full-text review, 17 were cost-utility analyses and 2 
were utility generation reports related to breast cancer and reconstruction (Table 2.4). Of 
the cost-utility analyses, 9 assessed the relative costs and benefits of autologous 
reconstruction, 6 assessed those of implant-based reconstruction and 4 did not specify the 
reconstructive modality used but compared all reconstruction techniques to mastectomy 
alone. Of the included studies, only one specified unilateral or bilateral reconstruction. 
Further, only 5 studies specified timing of reconstruction as either immediate or delayed. 
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Table 2.4 Characteristics of Included Studies 
Author Design CUA Model Utility Generation Contribution to 
Pooled Estimate   Population Intervention Reconstruction Methods Population Utility 
Metric 
Number 
Surveyed 
Chatterjee et 
al. 2013(21) 
CUA Free 
Autologous 
Reconstruction 
Laser-Assisted 
Indocyanine 
Green 
Angiography 
Free Flap Expert Opinion TTO 
VAS 
10 Included 
Grover et al. 
2013(22) 
CUA Breast 
Reconstruction 
Reconstruction 
Method 
Direct to implant, 
expander-implant, 
pedicled flap, free flap, 
pedicled latissimus dorsi 
flap with implant 
Expert Opinion VAS 9 Included 
Hummelink et 
al. 2017(23) 
CUA Free 
Autologous 
Reconstruction 
3D Planning 
with CT 
Angiography 
DIEP Flap Literature 
Review(21) 
 
N/A Included
2
 
Ibrahim et al. 
2015(24) 
Utility 
Report 
Breast 
Reconstruction 
N/A Breast reconstruction 
without nipple 
reconstruction 
General 
Population 
TTO 
VAS 
SG 
103 Included 
Keskey et al. 
2017(25) 
CUA Breast Cancer Unilateral 
Mastectomy vs. 
Contralateral 
Prophylactic 
Mastectomy 
With or without 
reconstruction 
Literature 
Review(26–29) 
 
N/A Excluded 
                                                        
2 Values were obtained from literature but Hummelink et al. report a value that was not reported in source article so it was included to incorporate this additional 
HSUV. 
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Table 2.4 Characteristics of Included Studies 
Author Design CUA Model Utility Generation Contribution to 
Pooled Estimate   Population Intervention Reconstruction Methods Population Utility 
Metric 
Number 
Surveyed 
Krishnan et al. 
2014(30) 
CUA Implant-Based 
Reconstruction 
Acellular 
Dermal Matrix 
(ADM) 
Expander-implant 
immediate with or without 
ADM 
Expert Opinion TTO 
VAS 
5 Included 
Krishnan et al. 
2013(31) 
CUA Implant-Based 
Reconstruction 
Acellular 
Dermal Matrix 
(ADM) vs 
Autologous 
Dermal Flaps 
Single-stage, implant-
based immediate with 
ADM or autologous 
dermal flap 
Expert Opinion TTO 
VAS 
10 Included 
Krishnan et al. 
2015(32) 
CUA Free 
Autologous 
Reconstruction 
Reconstruction 
Method 
DIEP, muscle sparing 
TRAM 
Literature 
Review(33) 
 
N/A Excluded 
Krishnan et al. 
2016(34) 
CUA Implant-Based 
Reconstruction 
Reconstruction 
Method 
Single-stage, expander 
implant 
Expert Opinion VAS 15 Included
3
 
Malin et al. 
2002(35) 
CUA Breast Cancer N/A Unspecified Literature 
Review(36)  
 
N/A Excluded 
Matros et al. 
2015(37) 
CUA Breast 
Reconstruction 
Reconstruction 
Method 
Implant-based, autologous 
perforator flaps 
Patients BREASTQ 526 Excluded
4
 
                                                        
3 Utilities not reported by Krishnan et al. so were derived based on QALYs and health state duration for use in this study. 
4 Utilities not reported and could not be derived based on reported health state information. 
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Table 2.4 Characteristics of Included Studies 
Author Design CUA Model Utility Generation Contribution to 
Pooled Estimate   Population Intervention Reconstruction Methods Population Utility 
Metric 
Number 
Surveyed 
Offodile et al. 
2015(38) 
CUA Free 
Autologous 
Reconstruction 
Preoperative CT 
Angiography 
Free flap Expert Opinion TTO 
VAS 
Not 
Reported 
Excluded 
Peasgood et al. 
2010(26) 
Utility 
Report 
Breast Cancer N/A Unspecified Literature 
Review 
 
N/A Excluded 
Preminger et 
al. 2008(39) 
CUA Breast 
Reconstruction 
Reconstruction 
Method 
Implant-based, free TRAM Literature 
Review,  
Author 
Assumption  
 
N/A Excluded 
Razdan et al. 
2016(40) 
CUA Locally-
Advanced 
Breast Cancer 
Reconstruction 
Method 
Mastectomy alone, 
immediate expander-
implant, delayed 
autologous 
Patients BREASTQ 343 Included
5
 
Roberts et al. 
2014(27) 
CUA Breast Cancer Unilateral 
Mastectomy vs. 
Contralateral 
Prophylactic 
Mastectomy 
Expander-implant Literature 
Review 
 
N/A Excluded 
Thoma et al. 
2008(41) 
CUA Free 
Autologous 
Reconstruction 
Reconstruction 
Method 
DIEP, SIEA Literature 
(Thoma et al. 
2004) 
 
N/A Excluded 
Thoma et al. 
2003(42) 
CUA Breast 
Reconstruction 
Reconstruction 
Method 
Free TRAM, pedicled 
TRAM 
Expert Opinion VAS 33 Included 
                                                        
5 Included because utilities were reported for successful surgery. However, utilities were not reported for complication health states and could not be derived 
based on reported health state information. 
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Table 2.4 Characteristics of Included Studies 
Author Design CUA Model Utility Generation Contribution to 
Pooled Estimate   Population Intervention Reconstruction Methods Population Utility 
Metric 
Number 
Surveyed 
Thoma et al. 
2004(33) 
CUA Breast 
Reconstruction 
Reconstruction 
Method 
DIEP, free TRAM Expert Opinion VAS 32 Included 
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2.3.3. Utility Generation 
Utilities were generated through expert opinion surveys in 7 studies, through literature 
review in 9 studies, through patient questionnaires in 2 studies and through a survey of 
the general population in 1 study. Of the studies that generated utilities from expert 
opinion, 4 administered time trade-off surveys or visual analogue scales to experts 
depending on respondent familiarity with each tool while 4 administered visual analogue 
scales alone. Only 1 study used standard gamble to generate utilities. Of the 2 articles that 
surveyed patients to generate utilities, both used the BREAST-Q™, a validated, patient-
reported outcome measure which has been widely used.(43) Of the cost-utility analyses 
that obtained utilities from the literature, 4 cited articles that generated utilities through 
expert opinion (TTO or VAS),(23,32,35,38) one cited a value generated for an “absent 
breast” health state using the Health and Activity Limitation Index(39) and the remainder 
were unspecified. 
 
2.3.4. Health States 
Overall, the 19 included articles reported utility values for 35 distinct health states of 
which 17 were related to breast reconstruction. However, definitions and durations of 
health states varied by study and were inconsistently reported. 
 
2.3.5. Utility Values 
Only the 10 studies that generated original utility values were included in the pooled 
estimates (Table 2.5). Successful surgery (i.e., without complications) was reported by 8 
studies of which 4 studies reported utilities for multiple reconstructive techniques 
resulting in 15 observations that contributed to the pooled estimate of 0.73 (95%CI 0.59-
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0.87). Successful autologous breast reconstruction had a higher average utility than 
successful implant-based breast reconstruction. Complication states varied widely, with 
total flap loss associated with the lowest utility (0.55 95%CI 0.40-0.71), which was worse 
than the utility of mastectomy alone (0.60 95%CI 0.51-0.68). The utility for hematoma 
(0.73 95%CI 0.59-0.87) approached that of successful surgery; however, this may be 
explained by the higher utilities ascribed to the hematoma health state following 
autologous reconstruction and the heavier weighting of these studies due to the greater 
number of individuals surveyed for utility generation. Only 3 studies reported utility 
values for explantation or capsular contracture health states. 
 
 
 
  
Table 2.5 Pooled Health State Utility 
Values 
   
  
Health State Mean Utilitya  SDa Nb Referencesc  
Successful Breast Reconstruction 0.73 0.07 15 (21,22,30,31,33,34,40,42)  
Implant-Based Breast Reconstruction 0.70 0.02 8 (22,30,31,34,40)  
Autologous Breast Reconstruction 0.79 0.09 6 (21,22,33,40,42)  
Total Flap Loss 0.55 0.07 6 (21,22,33,42)  
Partial Flap Necrosis 0.72 0.02 8 (21,22,33,42)  
Mastectomy Skin Necrosis 0.68 0.04 5 (21,30,31,42)  
Hematoma  0.73 0.07 9 (21,30,31,33,34,42)  
Infection 0.67 0.09 9 (21,22,30,31,34,42)  
Explantation 0.613 0.04 3 (30,31)  
Capsular Contracture Grade III/IV 0.59 0.01 4 (30,34)  
Revision 0.62 0.01 2 (34)  
Nipple Deformity 0.89 N/A 3  (24)  
Mastectomy Alone 0.60 0.04 2 (22,40)  
a Weighted mean and SD, b Number of observations, c discrepancies between number of observations 
and number of references is due to some citations reporting utilities for multiple reconstructive 
techniques 
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2.3.6. Methodological Quality 
Overall, none of the studies met all of the requirements for the NICE reference case. Only 
two studies surveyed the patient population for health status assessment. Both of these 
used the BREAST-Q which is a validated condition-specific instrument.(37,40) However, 
at the time of the analysis, the BREAST-Q did not have preference weighting available so 
an average of the domain scores was used.(37,40) Neither of these studies report 
demographic information for the respondents of the BREAST-Q so it is not possible to 
know if the population sampled is representative of the population modelled. Likewise, 
response rates and attrition are not reported. The CHEERS guidelines recommend 
mapping for non-preference weighted instruments.(19) This was not performed in either 
of the aforementioned cost-utility analyses. Further, the method by which the authors 
generated utilities for specific health states based on the temporal association to survey 
completion is unclear. 
 
The remainder of the studies that generated unique utility values solicited expert opinion 
using direct elicitation methods. This methodology is not recommended by either the 
NICE guidelines or the CHEERs guidelines. 
 
2.3.7. Heterogeneity 
None of the articles reported confidence intervals for the health state utility values so 
neither a formal meta-analysis nor a quantitative assessment of heterogeneity could be 
performed.  
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2.4. Discussion 
Cost-utility analyses have an increasingly important role in resource planning given the 
anticipated increased demand for health care services required by an aging 
population.(44) To conduct high-quality analyses, the estimates of health state utility 
values must reflect the perceptions of society at large.(45) In the breast reconstruction 
literature, a number of CUAs have been conducted. These have used health state utility 
values from a variety of sources. This systematic review attempted to catalogue the 
methods of developing or choosing HSUVs in breast reconstruction-related CUAs and 
aggregate published values into pooled estimates. 
 
The results of this systematic review show that 50% of CUAs in breast reconstruction 
select utility values previously reported in the literature, whether from single sources or 
published meta-analyses. The remainder generated utility values independently, the 
majority through direct elicitation surveys of physicians with only two studies obtaining 
utility values by direct patient survey. There is considerable debate over the best group to 
survey in health state utility value generation.(9,46) Proponents of patient valuation of 
health states argue that patients know their own health and disease status best. However, 
reported values may be higher due to the tendency of patients to adapt to their existing 
health state over time. This may result in smaller than expected improvements in quality 
of life with new interventions.(9) Others advocate for health status assessment by the 
general population since economic analyses are meant to reflect values held by 
individuals from diverse perspectives to be representative of a broader, societal 
perspective.(47) Population-derived utilities are preferred for economic evaluations 
designed to inform public policy decision-making since these utilities may be more 
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representative of values held by the general population.   
 
While use of generic health status measures is recommended in cost-utility analyses, none 
of the included studies used such a measure, favouring instead direct-elicitation 
techniques. Although there are many published studies that use generic health status 
measures, these are limited by poor sensitivity to changes in health status in the post-
surgical breast reconstruction population. In breast surgery, and breast reconstruction in 
particular, many of the generic patient outcome measures are not sensitive to changes in 
quality of life associated with early and late post-operative health states.(48) As such, 
other scales have been developed to evaluate quality of life in these situations, such as the 
BREAST-Q and the BRECON-31.(43,49) However, these measures do not yet have 
preference-weighting and, therefore, are limited in their use with respect to utility 
generation. 
 
The majority of cost-utility analyses included in the quantitative analysis used direct 
elicitation techniques, typically administered to medical experts. Although 3 studies did 
report using time trade-off to generate utilities, 7 studies reported using visual analogue 
scales for utility generation. Visual analogue scale is advantageous in that it is easy to 
administer and understand. However, it is limited by multiple sources of bias and has 
poor grounding in economic theory.(8,10) Recognition of these limitations is important 
when borrowing values from the literature for utility estimates. 
 
This systematic review has several strengths. It provides a summary of published cost-
utility analyses in breast reconstruction with an emphasis on the method of utility 
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generation. In addition, the quantitative analysis summarizes the published utilities as 
weighted averages which can be used in future cost-utility analyses. Unfortunately, the 
available studies included in the systematic review did not publish confidence intervals 
for utility values. Therefore, a formal meta-analysis and quantitative assessment of 
heterogeneity could not be performed. However, possible sources of heterogeneity among 
reported utility values include variability in definition of health states, duration of health 
states and method of health status assessment (i.e., direct versus indirect elicitation, 
generic or diseases specific measures, preference-weighted or non-preference weighted 
measures). Despite these limitations, this review contextualizes the existing literature on 
economic analyses in breast reconstruction and highlights discrepancies between 
commonly used methods for health status assessment and existing guidelines.  
 
2.5. Conclusions 
Utility values in breast reconstruction are variable and affected by surgical technique and 
post-operative outcomes. The most commonly used methods of health status assessment 
in the breast reconstruction literature are the VAS and TTO. This analysis can serve as a 
reference for utilities and health states for future CUAs in breast reconstruction. 
 
2.6. References 
1.  Platt J, Zhong T, Moineddin R, Booth GL, Easson AM, Fernandes K, et al. 
Geographic Variation Immediate and Delayed Breast Reconstruction Utilization in 
Ontario, Canada and Plastic Surgeon Availability: A Population-Based 
Observational Study. World J Surg. 2015;39(8):1909–21.  
2.  Albornoz CR, Bach PB, Mehrara BJ, Disa JJ, Pusic AL, McCarthy CM, et al. A 
Chapter 2 
 44 
Paradigm Shift in U.S. Breast Reconstruction:  Increasing Implant Rates. Plast 
Reconstr Surg. 2013;131(1).  
3.  Macadam SA, Ho AL, Cook EFJ, Lennox PA, Pusic AL. Patient satisfaction and 
health-related quality of life following breast reconstruction: patient-reported 
outcomes among saline and silicone implant recipients. Plast Reconstr Surg. 
United States; 2010;125(3):761–71.  
4.  Jansen LA, Macadam SA. The Use of AlloDerm in Postmastectomy Alloplastic 
Breast Reconstruction: Part II. A Cost Analysis. Plast Reconstr Surg. 
2011;127(6):2245–54.  
5.  Head LK, McKay DR. Economic Comparison of Hand-Sutured and Coupler-
Assisted Microvascular Anastomoses. J Reconstr Microsurg. 25.09.2017. 
2018;34(01):71–6.  
6.  Cape JD, Beca JM, Hoch JS. Introduction to Cost-Effectiveness Analysis for 
Clinicians. Univ Toronto Med J. 2013;90(3):103–5.  
7.  Hoch JS, Dewa CS. A Clinician’s Guide to Correct Cost-Effectiveness Analysis: 
Think Incremental Not Average. Can J Psychiatry. SAGE Publications Inc; 2008 
Apr 1;53(4):267–74.  
8.  Brazier J, Deverill M, Green C. A Review of the Use of Health Status Measures in 
Economic Evaluation. J Health Serv Res Policy. SAGE Publications; 1999 Jul 
1;4(3):174–84.  
9.  Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and 
utilities. Br Med Bull. 2010 Dec 1;96(1):5–21.  
10.  Torrance GW, Feeny D, Furlong W. Visual Analog Scales: Do They Have a Role 
in the Measurement of Preferences for Health States? Med Decis Mak. SAGE 
Chapter 2 
 45 
Publications Inc STM; 2001 Aug 1;21(4):329–34.  
11.  Pusic AL, Chen CM, Cano S, Klassen A, McCarthy C, Collins ED, et al. 
Measuring Quality of Life in Cosmetic and Reconstructive Breast Surgery: A 
Systematic Review of Patient-Reported Outcomes Instruments. Plast Reconstr 
Surg. 2007;120(4):823–37.  
12.  Pusic AL, Chen CM, Cano S, Klassen A, McCarthy C, Collins ED, et al. 
Measuring quality of life in cosmetic and reconstructive breast surgery: a 
systematic review of patient-reported outcomes instruments. Plast Reconstr Surg. 
United States; 2007;120(4):823–9.  
13.  EuroQol Group. EuroQol - a new facility for the measurement of health-related 
quality of life. Health Policy (New York). 1990;16(3):199–208.  
14.  Bosch JL, Hunink M. The Relationship between Descriptive and Valuational 
Quality-of-life Measures in Patients with Intermittent Claudication. Med Decis 
Mak. Sage Publications; 1996 Aug;16(3):217–25.  
15.  Chuback J, Yarascavitch B, Yarascavitch A, Kaur MN, Martin S, Thoma A. 
Measuring utilities of severe facial disfigurement and composite tissue 
allotransplantation of the face in patients with severe face and neck burns from the 
perspectives of the general public, medical experts and patients. Burns. 
2015;41(7):1524–31.  
16.  Papaioannou D, Brazier J, Paisley S. Systematic Searching and Selection of Health 
State Utility Values from the Literature. Value Heal. Elsevier; 2013 Jun 
1;16(4):686–95.  
17.  Meregaglia M, Cairns J. A systematic literature review of health state utility values 
in head and neck cancer. Health Qual Life Outcomes. London: BioMed Central; 
Chapter 2 
 46 
2017 Sep 2;15:174.  
18.  National Institute for Health and Care Excellence. Guide to the methods of 
technology appraisal 2013 [Internet]. 2013. Available from: 
https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-
technology-appraisal-2013-pdf-2007975843781 
19.  Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - 
Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation 
Publication Guidelines Good Reporting Practices Task Force. Value Heal. 
Elsevier; 2013 Mar 1;16(2):231–50.  
20.  Bland JM, Kerry SM. Weighted comparison of means. BMJ. 1998 Jan 
10;316(7125):129.  
21.  Chatterjee A, Krishnan NM, Van Vliet MM, Powell SG, Rosen JM, Ridgway EB. 
A Comparison of Free Autologous Breast Reconstruction with and without the Use 
of Laser-Assisted Indocyanine Green Angiography: A Cost-Effectiveness 
Analysis. Plast Reconstr Surg. 2013;131(5):693e–701e.  
22.  Grover R, Padula W V, Van Vliet M, Ridgway EB. Comparing Five Alternative 
Methods of Breast Reconstruction Surgery:  A Cost-Effectiveness Analysis. Plast 
Reconstr Surg. 2013;132(5).  
23.  Hummelink S, Gerrits JGW, Schultze Kool LJ, Ulrich DJO, Rovers MM, Grutters 
JPC. The merits of decision modelling in the earliest stages of the IDEAL 
framework: An innovative case in DIEP flap breast reconstructions. J Plast 
Reconstr Aesthet Surg. Netherlands; 2017;70(12):1696–701.  
24.  Ibrahim AMS, Sinno HH, Izadpanah A, Vorstenbosch J, Dionisopoulos T, Mureau 
Chapter 2 
 47 
MAM, et al. Nipple-areolar Complex Reconstruction following Postmastectomy 
Breast Reconstruction: A Comparative Utility Assessment Study. Plast Reconstr 
surgery Glob open. United States; 2015;3(4):e380.  
25.  Keskey RC, LaJoie AS, Sutton BS, Kim IK, Cheadle WG, McMasters KM, et al. 
Cost-effectiveness Analysis of Contralateral Prophylactic Mastectomy Compared 
to Unilateral Mastectomy with Routine Surveillance for Unilateral, Sporadic 
Breast Cancer. Ann Surg Oncol. United States; 2017;24(13):3903–10.  
26.  Peasgood T, Ward SE. Health-state utility values in breast cancer. Expert Rev 
Pharmacoeconomics Outcomes Res. S. E. Ward, School of Health and Related 
Research, University of Sheffield, Regents Court, Regent Street, Sheffield, S1 
4DA, United Kingdom. E-mail: s.e.ward@sheffield.ac.uk: Expert Reviews Ltd. (2 
Albert Place, London N3 1QB, United Kingdom); 2010;10(5):553–66.  
27.  Roberts A, Habibi M, Frick KD. Cost-effectiveness of contralateral prophylactic 
mastectomy for prevention of contralateral breast cancer. Ann Surg Oncol. United 
States; 2014 Jul;21(7):2209–17.  
28.  Oestreicher N, Ramsey SD, Linden HM, McCune JS, van’t Veer LJ, Burke W, et 
al. Gene expression profiling and breast cancer care: what are the potential benefits 
and policy implications? Genet Med. United States; 2005;7(6):380–9.  
29.  Ko CY, Maggard M, Livingston EH. Evaluating health utility in patients with 
melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-
based assessment. J Surg Res. United States; 2003 Sep;114(1):1–5.  
30.  Krishnan NM, Chatterjee A, Rosenkranz KM, Powell SG, Nigriny JF, Vidal DC. 
The cost effectiveness of acellular dermal matrix in expander-implant immediate 
breast reconstruction. J Plast Reconstr Aesthet Surg. Netherlands; 2014;67(4):468–
Chapter 2 
 48 
76.  
31.  Krishnan NM, Chatterjee A, Van Vliet MM, Powell SG, Rosen JM, Nigriny JF. A 
comparison of acellular dermal matrix to autologous dermal flaps in single-stage, 
implant-based immediate breast reconstruction: a cost-effectiveness analysis. Plast 
Reconstr Surg. United States; 2013;131(5):953–61.  
32.  Krishnan NM, Purnell C, Nahabedian MY, Freed GL, Nigriny JF, Rosen JM. The 
cost effectiveness of the DIEP flap relative to the muscle-sparing TRAM flap in 
postmastectomy breast reconstruction. Plast Reconstr Surg. United States; 
2015;135(4):948–58.  
33.  Thoma A, Veltri K, Khuthaila D, Rockwell G. Comparison of the deep inferior 
epigastric perforator flap and free transverse rectus abdominis myocutaneous flap 
in postmastectomy reconstruction: A cost-effectiveness analysis. Plast Reconstr 
Surg. A. Thoma, 206 James Street South, Hamilton, Ont. L8P 3A9, Canada. E-
mail: athoma@mcmaster.ca: Lippincott Williams and Wilkins (351 West Camden 
Street, Baltimore MD 21201-2436, United States); 2004;113(6):1650–61.  
34.  Krishnan NM, Fischer JP, Basta MN, Nahabedian MY. Is Single-Stage Prosthetic 
Reconstruction Cost Effective? A Cost-Utility Analysis for the Use of Direct-to-
Implant Breast Reconstruction Relative to Expander-Implant Reconstruction in 
Postmastectomy Patients. Plast Reconstr Surg. United States; 2016;138(3):537–47.  
35.  Malin JL, Keeler E, Wang C, Brook R. Using cost-effectiveness analysis to define 
a breast cancer benefits package for the uninsured. Breast Cancer Res Treat. 
Netherlands; 2002;74(2):143–53.  
36.  Hillner BE, Smith TJ. Efficacy and Cost Effectiveness of Adjuvant Chemotherapy 
in Women with Node-Negative Breast Cancer. N Engl J Med. Massachusetts 
Chapter 2 
 49 
Medical Society; 1991 Jan 17;324(3):160–8.  
37.  Matros E, Albornoz CR, Razdan SN, Mehrara BJ, Macadam SA, Ro T, et al. Cost-
Effectiveness Analysis of Implants versus Autologous Perforator Flaps Using the 
BREAST-Q. Plast Reconstr Surg. 2015;135(4):937–46.  
38.  Offodile AC, Chatterjee A, Vallejo S, Fisher CS, Tchou JC. A cost-utility analysis 
of the use of preoperative computed tomographic angiography in abdomen-based 
perforator flap breast reconstruction. Plast Reconstr Surg. United States; 
2015;135(4):662e–669e.  
39.  Preminger BA, Pusic AL, McCarthy CM, Verma N, Worku A. How should 
quality-of-life data be incorporated into a cost analysis of breast reconstruction? A 
consideration of implant versus free TRAM flap procedures. Plast Reconstr Surg. 
P. G. Cordeiro, Plastic and Reconstructive Surgery Service, Department of 
Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, 
NY 10021, United States. E-mail: cordeirp@mskcc.org: Lippincott Williams and 
Wilkins (351 West Camden Street, Baltimore MD 21201-2436, United States); 
2008;121(4):1075–82.  
40.  Razdan SN, Cordeiro PG, Albornoz CR, Ro T, Cohen WA, Mehrara BJ, et al. 
Cost-Effectiveness Analysis of Breast Reconstruction Options in the Setting of 
Postmastectomy Radiotherapy Using the BREAST-Q. Plast Reconstr Surg. United 
States; 2016;137(3):510e–517e.  
41.  Thoma A, Jansen L, Sprague S, P Stat ED. A comparison of the superficial inferior 
epigastric artery flap and deep inferior epigastric perforator flap in postmastectomy 
reconstruction: A cost-effectiveness analysis. Can J Plast Surg. Canada; 
2008;16(2):77–84.  
Chapter 2 
 50 
42.  Thoma A, Khuthaila D, Rockwell G, Veltri K. Cost-utility analysis comparing free 
and pedicled TRAM flap for breast reconstruction . Microsurgery. Wiley 
Subscription Services, Inc., A Wiley Company; 2003 Jan 1;23(4):287–95.  
43.  Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development 
of a new patient-reported outcome measure for breast surgery: the BREAST-Q. 
Plast Reconstr Surg. United States; 2009;124(2):345–53.  
44.  Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. 
Aging with multimorbidity: A systematic review of the literature. Ageing Res Rev. 
2011;10(4):430–9.  
45.  Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and 
Medicine. Oxford University Press, USA; 1996.  
46.  Drummond M, Brizner D, Gold M, Kind P, McGuire A, Nord E. Toward a 
Consensus on the QALY. Value Heal. Blackwell Publishing; 2009 
Mar;12(Supplement 1):S31–5.  
47.  Muennig P, Bounthavong M. Cost-Effectiveness Analysis in Health: A Practical 
Approach. 3rd ed. San Francisco: Wiley; 2016.  
48.  Velanovich V. Experience with a generic quality of life instrument in a general 
surgical practice. Int J Surg Investig. 2000;1(5):447—452.  
49.  Temple-Oberle CF, Ayeni O, Cook EF, Bettger-Hahn M, Mychailyshyn N, 
MacDermid J. The breast reconstruction satisfaction questionnaire (BRECON-31): 
an affirmative analysis. J Surg Oncol. United States; 2013;107(5):451–5.  
 
 
 
Chapter 3 
 51 
3. Chapter 3: A Cost-Utility Analysis of Saline and Silicone Implants in Breast 
Reconstruction 
 
Overview 
This chapter outlines considerations and parameters in designing cost-utility-
analyses. A cost-utility analysis examining saline and silicone implants in the context 
of immediate, unilateral, implant-based breast reconstruction is described. Results 
demonstrate silicone implants to be cost-effective despite higher baseline costs. This 
analysis supports ongoing funding of silicone implants due to associated quality of 
life improvements.6 
 
3.1. Introduction 
Breast reconstruction is a recognized component of the breast cancer treatment pathway. 
As breast cancer mortality has decreased, management has increasingly focused on 
interventions that result in improved quality of life in the survivorship period. There are 
many approaches and adjuncts to breast reconstruction with diverse cost and 
complication profiles. 
 
In the context of breast reconstruction, adjuncts such as the use of CT angiography and 
acellular dermal matrix have been demonstrated to be cost-effective in the American 
health care system.(1,2) However, there remain a number of other parameters that are 
unaccounted for in the existing cost-effectiveness literature. For instance, implant options 
                                                        
6A portion of the work covered in Chapters 1 and 2 is included here as part of the Integrated Article 
Format. 
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are highly heterogeneous in terms of both cost and outcome profiles. One cross-sectional 
survey of patients undergoing breast reconstruction showed higher quality of life among 
patients who received silicone implants as compared to saline implants.(3) However, 
saline implants can offer a significant cost savings. Further, rates of complications such 
as capsular contracture and implant rupture may result in downstream costs to the patient 
and health care system. These variations are not accounted for in the existing cost-
effectiveness literature; thus, it is important to delineate which is truly the cost-effective 
option. 
 
Cost-utility analysis facilitates integration of these outcomes, describing costs in 
monetary units and outcomes in terms of health-related quality of life. This form of 
economic analysis provides useful insights into efficient allocation of limited healthcare 
resources. Although there are many factors that influence health-care spending decisions 
including disease burden, social consensus, inequality and rule of rescue (i.e. perceived 
duty to save lives in danger), cost-effectiveness analysis can be used to identify effective 
treatments within resource constraints. (4) 
 
Constructing a cost-effectiveness analysis requires identification of costs and effects for 
all relevant stakeholders. To develop such a model, perspective (i.e., relevant 
stakeholders) must be considered in addition to health states and associated probabilities, 
utilities and costs.  
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3.1.1. Considerations in Designing Cost-Utility Analyses  
3.1.1.1. Perspective 
The perspective of the cost-utility analysis determines which costs and outcomes should 
be included. Decision-makers in health care include patients, clinics, hospitals, insurers 
and public funders of health care. The societal perspective examines all costs and 
outcomes relevant to society at large.(5) In practice, this can be challenging to measure as 
documentation of patient costs requires patient enrollment and logging of incurred costs. 
In the plastic surgery literature, the perspective of the hospital or third-party payer is 
commonly adopted as these organizations bear the majority of costs relating to surgical 
procedures. This is consistent with the recommendations from the Second Panel on Cost-
Effectiveness in Health and Medicine which recommends the health care perspective as 
the reference case.(6)  
 
3.1.1.2. Health States, Probabilities and Utilities 
Individual states of health are termed “health states.” These include individual well and 
unwell conditions that collectively comprise a person’s health status. Health states 
include concrete health outcomes, such as death, as well as more nuanced improvements 
or deteriorations such as recovery of extremity function, ability to walk or chronic 
pain.(7) In breast reconstruction, health states are related to technique and outcome. For 
instance, abdominal morbidity can be associated with the use of abdominal-based flaps 
while capsular contracture can occur after implant insertion. To determine the net cost-
effectiveness of different types of implants in breast reconstruction, all relevant health 
states must be identified in addition to the associated probabilities, costs and quality of 
life of each health state. 
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3.1.1.3. Costs 
There are varying levels of precision in estimating costs incurred by hospitals (Table 3.1). 
Types of costs can be broken down into direct and indirect costs. Direct costs include 
costs related to patient care (e.g., nursing, medications, investigations, etc.). Indirect costs 
are those not directly related to patient care but that are nonetheless required to support 
the patient, hospital, organization (e.g., health records, administration, maintenance, 
patient out-of-pocket costs etc.). Costs can be calculated through multiple approaches. 
The most accurate method of costing is micro-costing which accounts for all resources 
used  (e.g., medications, laboratory tests, length of stay in a particular ward, etc.).(8) 
Unfortunately, it is challenging to do this outside of a prospective clinical study whereby 
costs incurred can be tracked reliably. Average daily costs are the least accurate in which 
total cost to the hospital per day is averaged over all categories of patients.(8) This 
method does not allow for differentiation between patients that use more services than 
others, such as patients in an intensive care unit as compared to those on low-acuity 
wards. Other approaches include calculating average costs for case-mix groups, disease-
specific per diem costs and generic per diem costs. These are ultimately influenced by 
how specifically cases and diseases are defined (e.g., patients undergoing mastectomy 
with immediate reconstruction versus patients undergoing oncologic surgery in general). 
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Table 3.1 Costing Methods 
Method Description 
Micro-costing All resources used are estimated and the costs for each are summed. 
Case-mix costing Patients are divided into clinically-meaningful groups based on type of case 
and length of stay. 
Per diem costing Total resource use and expenditure are divided by number of days of 
service provided to generate average daily cost. 
 
3.1.2. Rationale and Hypothesis 
Given the increasing rate of implant-based reconstruction it is essential to delineate the 
cost-effectiveness of alternative implant-based treatments. The cost-effectiveness of 
different implant types has not yet been analyzed; however, saline and silicone implants 
vary in complication rates, costs and associated quality of life. This study examined the 
cost-utility of saline and silicone implants in the context of immediate, unilateral, 
implant-based breast reconstruction. 
 
3.2. Methods 
3.2.1. Perspective 
The perspective of a third-party payer was adopted for this analysis, specifically the 
Ontario Ministry of Health and Long-Term Care (MOHLTC). Relevant costs included 
operating room expenses, clinic costs and physician costs. Home care costs were not 
accounted for in this analysis. It was not possible to obtain the cost to the patient in terms 
of productivity losses and out-of-pocket expenses since secondary data were used for this 
analysis. As a result, a societal perspective was not considered. 
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3.2.2. Population 
The population was assumed to be women with stage I or II breast cancer seeking 
unilateral mastectomy with implant-based reconstruction in the immediate setting. The 
age of the cohort was assumed to be 52.5 years based on average age at diagnosis of 
breast cancer in Canada.(9) Life-expectancy was assumed to be 83.9 years, derived from 
Canadian census data, since life-expectancy of stage I and II breast cancer survivors 
approaches that of age-matched controls.(10,11) 
 
3.2.3. Time Horizon 
The time horizon for the analysis was assumed to be 31.4 years based on difference 
between life-expectancy and age at diagnosis.  
 
3.2.4. Health States 
A review of the surgical literature was conducted to identify relevant complications 
associated with implant type following implant-based breast reconstruction. These 
complications included capsular contracture, implant rupture, unplanned revision and 
explantation. Complications related to implant use but unrelated to implant filler type 
(e.g., breast-implant associated anaplastic large cell lymphoma, hematoma, etc.) were not 
included. The complications were defined as distinct health states (Table 3.2) with 
associated probabilities, costs and utilities. Assumptions regarding duration of health 
states and treatment course were based on institutional practice patterns. 
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Table 3.2 Health State Descriptions 
Health State Description and Assumptions  
Successful Surgery Initial pre-surgical consultation with plastic surgeon, followed by outpatient 
surgery. Surgery assumed to be 2.5 h duration. Patient returns for follow-up visit 
at 1 week, 2 weeks, 6 weeks and 6 months.  
Capsular Contracture 
Grade III/IV 
Patient develops significant capsular contracture requiring surgical capsulotomy 
as outpatient. Patient keeps original implants. In addition to costs of successful 
surgery, patient requires repeat clinic visit to discuss problem prior to surgical 
intervention. Surgery assumed to be 2 h duration. Patient returns for follow-up 
visit at 2 weeks, 6 weeks and 6 months. Duration of health state assumed to be 1 
year followed by a return to successful surgery health state. 
Explantation Patient develops problem requiring or preferring implant removal without 
replacement. In addition to costs of successful surgery, patient requires repeat 
clinic visit to discuss problem prior to surgical intervention. Surgery assumed to 
be 1 h duration as outpatient. Patient returns for follow-up visit at 2 weeks, 6 
weeks and 6 months. Duration of health state assumed to be 1 year followed by 
return to mastectomy defect health state. 
Unplanned Revision Patient develops clinical problem related to implant-based reconstruction. In 
addition to costs of successful surgery, patient requires repeat clinic visit to 
discuss problem prior to surgical intervention. Surgery assumed to be 2 h duration 
as outpatient. Patient returns for follow-up visit at 2 weeks, 6 weeks and 6 
months. Duration of health state assumed to be 1 year followed by return to 
successful surgery health state. 
Saline Implant 
Rupture 
Patient develops clinically evident deflation seeking implant replacement. In 
addition to costs of successful surgery, patient requires repeat clinic visit to 
discuss problem prior to surgical intervention. Surgery assumed to be 2 h duration 
as outpatient. Patient returns for follow-up visit at 2 weeks, 6 weeks and 6 
months. Duration of health state assumed to be 1 year followed by return to 
successful surgery health state. 
Silicone Implant 
Rupture 
Concern for rupture triggers presentation to plastic surgeon. Workup includes 
MRI followed by surgery for implant exchange. In addition to costs of successful 
surgery, patient requires repeat clinic visit to discuss problem prior to surgical 
intervention. Surgery assumed to be 2.5 h duration as outpatient. Patient returns 
for follow-up visit at 2 weeks, 6 weeks and 6 months. Duration of health state 
assumed to be 1 year followed by return to successful surgery health state. 
 
 
3.2.5. Costs 
The costs for implant-based reconstruction were based on values obtained from the Case-
Costing Centre at St. Joseph’s Health Care (SJHC) London. SJHC is a predominantly 
ambulatory care hospital with outpatient surgical facilities and an inpatient surgical ward. 
The Surgical Case Costing Centre at SJHC performs micro-costing for surgical 
procedures that are designated as Quality-Based Procedures by the Ontario MOHLTC. 
Quality-Based Procedures reflect clusters of clinically-related patients, diagnoses and 
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treatments that are used to direct improvements in health services and can be refined 
based on Canadian Classification of Health Intervention (CCI) codes.(12) Breast cancer 
surgeries, including both ablation and reconstruction, have been identified as Quality-
Based Procedures since 2016.(13) CCI codes were used to identify relevant procedures 
(Table 3.3) The cost estimates from the Case Costing Centre include all direct and 
indirect costs incurred during day surgery except physician costs. This includes operating 
room supplies, nursing, administrative overhead, pharmaceuticals, imaging and 
laboratory investigations for operating room supplies including implants, and acellular 
dermal matrix (Appendix 2). Overhead and operating room labour is estimated based on 
staffing and converted into a cost per minute of operating room time. The average cost of 
relevant CCI codes was used as the base cost for complication health states. Billing codes 
under the “Schedule of Benefits: Physician Services Under the Health Insurance Act” 
were used to estimate physician costs (Table 3.4).(14) 
 
Costs for implants were obtained from the Healthcare Materials Management Service 
(HMMS). HMMS works with both SJHC and London Health Sciences Centre (LHSC) to 
facilitate purchasing and inventory management through competitive bidding agreements. 
Costs for individual implant models are confidential and protected under the competitive 
bidding agreements so average prices of saline and silicone implants were used 
(Appendix 3).  
 
Costs for breast MRIs were obtained from the institutional radiology department. Breast 
MRI procedural costs, including supplies, technologists and storage, are $130 per exam. 
The cost of the MRI machine is approximately $2.5 million which is depreciated over 7 
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years at SJHC. Costs for radiologist reads of an MRI were obtained from the “Schedule 
of Benefits”. All costs were reported in 2017 Canadian Dollars (Appendix 4, Appendix 
5).  
 
Table 3.3 CCI Codes for Implant-Based Breast Reconstruction 
CCI Code Description 
1YM90LAPM Excision total with reconstruction, breast simple mastectomy with no node dissection 
without tissue with implantation of breast prosthesis 
1YM90LAPME Excision total with reconstruction, breast simple mastectomy with no node dissection 
using local flap with implantation of breast prosthesis 
1YM90LAPMK Excision total with reconstruction, breast using homograft with implantation of breast 
prosthesis 
1YM90LAQF Excision total with reconstruction, breast simple mastectomy with no node dissection 
without tissue with implantation of prosthesis and expander 
1YM90LAQFE Excision total with reconstruction, breast simple mastectomy with no node dissection 
using local flap with implantation of prosthesis and expander 
1YM90LATP Excision total with reconstruction, breast simple mastectomy with no node dissection 
without tissue with implantation of tissue expander 
1YM90LATPE Excision total with reconstruction, breast using local flap with implantation of tissue 
expander 
1YM90LATPK Excision total with reconstruction, breast using homograft with implantation of tissue 
expander 
1YM92LAPME Excision radical with reconstruction, breast modified or NOS using local flap with 
implantation of breast prosthesis 
1YM92LAPMK Excision radical with reconstruction, breast modified or NOS using homograft with 
implantation of.breast prosthesis 
1YM92LAQFE Excision radical with reconstruction, breast modified or NOS using local flap with 
implantation of prosthesis and expander 
1YM92LATPE Excision radical with reconstruction, breast modified or NOS using local flap with 
implantation of tissue expander 
1YM92LATPK Excision radical with reconstruction, breast modified or NOS using homograft with 
implantation of tissue expander 
1YM92TRPME Excision radical with reconstruction, breast extended [Urban] using local flap with 
implantation of breast prosthesis 
1YM92TRPMK Excision radical with reconstruction, breast extended.[Urban] using homograft with 
implantation of breast prosthesis 
1YM92TRQFE Excision radical with reconstruction, breast extended [Urban] using local flap with 
implantation of prosthesis and expander 
1YM92TRTPE Excision radical with reconstruction, breast extended [Urban] using local flap with 
implantation of tissue expander 
1YM92TRTPK Excision radical with reconstruction, breast extended.[Urban] using homograft with 
implantation of tissue expander 
1YM92WPPME Excision radical with reconstruction, breast super [Wangensteen] using local flap with 
implantation of breast prosthesis 
1YM92WPPMK Excision radical with reconstruction, breast super [Wangensteen] using homograft with 
implantation of breast prosthesis 
1YM92WPQFE Excision radical with reconstruction, breast super [Wangensteen] using local flap with 
implantation of prosthesis and expander 
1YM92WPTPE Excision radical with reconstruction, breast super [Wangensteen] using local flap with 
implantation of tissue expander 
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1YM92WPTPK Excision radical with reconstruction, breast super [Wangensteen] using homograft with 
implantation of tissue expander 
1YM90LAPM Excision total with reconstruction, breast simple mastectomy with no node dissection 
without tissue with implantation of breast prosthesis 
1YM91LAXXQ  Excision radical, breast using combined sources of tissue [e.g., local flap and tissue 
expander] modified or NOS 
1YM91LAPM  Excision radical, breast with implantation of breast prosthesis modified or NOS 
1YM91LATP   Excision (modified) radical, breast with implantation of tissue expander   
1YM88LAPM  Excision partial with reconstruction, breast without tissue with implantation of prosthesis 
1YM88LAPME   Excision partial with reconstruction, breast with local flap with implantation of 
prosthesis   
1YM88LAPMK  Excision partial with reconstruction, breast using homograft with implantation of 
prosthesis 
1YM88LAQF  Excision partial with reconstruction, breast without tissue with implantation of prosthesis 
and expander 
1YM88LAQFE  Excision partial with reconstruction, breast with local flap with implantation of prosthesis 
and expander 
1YM88LATP Excision partial with reconstruction, breast without tissue with implantation of tissue 
expander  
1YM88LATPE  Excision partial with reconstruction, breast with local flap with tissue expander 
1YM88LATPK Excision partial with reconstruction, breast using homograft with implantation of tissue 
expander  
 
 
  
Chapter 3 
 61 
Table 3.4 OHIP Billing Codes for Implant-Based Breast Reconstruction and Related Procedures 
Code Description 
R119 Breast mound creation by prosthesis as sole procedure  
R114 Revision of breast mound 
Z135 Open capsulotomy with or without replacement of breast prosthesis 
Z142 Removal of breast prosthesis  
Z182 Breast capsulectomy 
A085 Consultation  
A935 Special surgical consultation 
A086 Repeat consultation 
A083 Specific assessment 
A084 Partial assessment 
X446 Breast MRI unilateral or bilateral multi-slice sequence 
 
 
3.2.6. Probabilities 
The probabilities associated with clinically relevant health states for implant-based breast 
reconstruction with saline and silicone implants were obtained from a review of the 
literature. An electronic search of English-language articles published prior to November 
2017 was conducted. The search strategy was developed with assistance from a librarian 
familiar with systematic reviews. The search strategy included terms relevant to implant-
based breast reconstruction (Table 3.5). Results were screened for articles that examined 
saline versus silicone implants in the context of implant-based reconstruction and 
reported post-operative outcomes (Table 3.6). Citations were screened in two-stages. The 
first stage involved a review of title and abstract. Articles that met inclusion criteria or for 
which a determination could not be made were reviewed in the second stage in full text. 
Parameter estimates were extracted from relevant articles and weighted averages were 
calculated as appropriate.  
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Table 3.5 Search Strategy 
No. Search 
1 Breast Implantation/ or Breast Implants/ or (breast$ and (implant$ or prosthes$)).mp. (13358) 
2 exp *Breast/su and exp *"Prostheses and Implants"/ (846) 
3 or/1-2 (13374) 
4 follow-up studies.sh. or (follow-up or followup or follow$).mp. (3502738) 
5 3 and 4 (4030) 
6 Reoperation/ or (revision$ or re-vision$ or (repeat$ adj3 surg$) or re-operat$ or reoperat$ or re-
construct$ or reconstruct$ or mastectom$ or mammectom$).mp. or exp prosthesis failure/ or 
prosthesis-related infections/ or Implant Capsular Contracture/ or contracture$.mp. or exp treatment 
outcome/ or complication$.mp. or outcome$.tw. or (ae or co).fs. or incidence.sh. or incidence$.tw. or 
infect$.tw. (7255071) 
7 Comparative Study/ or (vs$1 or vs or versus or compar$).tw. or ((silicone$ or textured$ or round) 
and saline$).tw. or ((augmentation$ and ((revision$ or re-vision$) adj3 augmentation$)) or ((re-
construct$ or reconstruct$) and ((revision$ or re-vision$) adj3 reconstruct$))).tw. or (different$ adj2 
types$).tw. or (two adj2 different$).tw. or ((textured or rough) and smooth$).tw. (6570586) 
8 3 and 4 and 6 and 7 (1351) 
9 *Breast Implantation/ or *Breast Implants/ or (breast$.tw. and (implant$ or prosthes$).ti.) (6140) 
10 (re-construct$ or reconstruct$ or mastectom$ or mammectom$).tw. (282471) 
11 7 and 9 and 10 (774) 
12 8 or 11 (1685) 
13 limit 12 to english language (1582) 
14 13 not (exp Animals/ not (Human/ and exp Animals/)) (1537) 
15 meta analysis.mp 
16 14 and 15 (80) 
17  limit 14 to "review articles" (121) 
18 14 not 17 (1416) 
19 16 or 18 (1475) 
20  case report.ti. (213628) 
21 19 not 20 (1467) 
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Table 3.6 Systematic Review Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
 Population 
• implant-based breast reconstruction for 
therapeutic or prophylactic 
mastectomy) 
Design 
• RCT, retrospective or prospective 
cohort study, observational study 
• exposure: comparisons of saline versus 
silicone implants 
• outcomes: postoperative complications 
(immediate and delayed) 
Population 
• autologous reconstruction 
• reconstruction for non-oncologic entities (e.g., 
congenital/traumatic breast anomalies) 
Design 
• conference abstract 
• non-English language articles 
• case reports 
• letters 
• commentaries 
• non-systematic reviews 
• laboratory (animal or in vitro) studies 
 
The systematic review yielded 2185 records. The 1267 records which remained after 
duplicates were removed were screened by title and abstract. Of these, 23 records were 
reviewed in full text (Figure 3.1). There was a paucity of studies directly comparing 
saline versus silicone implants in implant-based breast reconstruction. Due to 
heterogeneity in study design and reported outcomes, none of the studies reported data 
useful for meta-analysis. Overall, there were a large number of retrospective and 
prospective non-randomized studies examining saline and silicone implants. However, 
few undertook direct comparisons between saline and silicone implants. At present, the 
best prospective data for saline and silicone implants comes from the post-market 
approval analyses of saline implants and silicone implant Core studies.(15–18) The 
silicone implant Core studies examined the fourth and fifth generation silicone implants 
most commonly used today. Ultimately, parameter estimates for this analysis were 
extracted from relevant Core studies and post-market approval data. 
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Figure 3.1 PRISMA Search Strategy Flow Diagram Probability Estimates 
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3.2.7. Utilities 
Utility values for clinically relevant health states were derived from a systematic review 
of the literature (Chapter 2). An electronic search of English-language articles published 
prior to November 2017 was conducted. The search strategy was conducted with 
assistance from a librarian familiar with systematic reviews. The search strategy included 
terms relevant to implant-based breast reconstruction and economic analysis (Table 2.2). 
Articles which generated unique utility values and reported number of individuals 
surveyed were included in a quantitative synthesis in which pooled estimates were 
generated. Weighted averages and standard deviations were calculated with weights 
based on study size. Additional values were generated from published quality of life data 
as appropriate.(3) 
 
Utilities were converted into quality adjusted life years by multiplying the utility by the 
duration of the health state and adding it to remaining life years multiplied by the utility 
of a successful surgery. The average age of women in the cohort was assumed to be 52.5 
based on average age at diagnosis of breast cancer.(9) Life-expectancy was assumed to be 
83.9 years, derived from Canadian census data since life-expectancy of stage I and II 
breast cancer survivors approaches that of age-matched controls.(10,11) 
 
3.2.8. Analysis 
A decision tree model was designed using TreeAge Pro 2017 © (Figure 3.1). Costs, 
QALYs and probabilities of each health state were incorporated into the model (Table 
3.7). Expected values for costs and outcomes were derived by the roll-back method and 
summed to generate the expected cost and utility of breast reconstruction with saline or 
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silicone implants. Costs and utilities were discounted at a rate of 3 percent per year. Onset 
of complications was assumed to be 10 years based on follow-up data from silicone 
implant Core studies and post-market approval data for saline implants.(15–18) The 
incremental cost-utility ratio (ICUR) was calculated using the following formula: 
!"#$ = &'()*+),	*./+	.0	/121*.3)	14(253+ − &'()*+),	*./+	.0	/5213)	14(253+&'()*+),	789:	.0	/121*.3)	14(253+ − &'()*+),	789:	.0	/5213)	14(253+	 
 
An intervention is considered cost-effective if the ICUR is less than the willingness-to-
pay (WTP) threshold for an additional quality-adjusted life year. The willingness-to-pay 
threshold was set at $50,000/QALY, as a conservative boundary and to be consistent with 
current literature.(19) 
 
One-way sensitivity analysis was performed to determine if the baseline decision analysis 
was robust by varying the complication rate of saline implants from 0 to 1 in increments 
of 0.02 and observing how this affected the ICUR. Other sensitivity analyses were 
conducted to examine different rates of capsular contracture, implant rupture and 
discounting rates. 
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Table 3.7 Health State Costs, Probabilities and Utilities  
  
Health State Cost SJHC ($) Cost LHSC 
($) 
Probability 
(citation) 
Range1 Utility2 
(citation) 
Range Duration 
(Years) 
QALYs3 
Silicone 
 
 
 
 
 
 
  
Successful Surgery 6988.12 5788.12 0.472 (15,16) (0.285, 0.545) 0.77 (3) (0.544, 
0.933) 
31.4 16.47 
Complication States 
 
 0.528  
 
 
  
Capsular Contracture 
Grade III/IV 
5946.71 4747.51 0.075 (15,16)  (0.092, 0.067) 0.59 (0.58, 0.6) 0.5 16.34 
Explantation 5750.66 4551.46 0.136 (15)  0.61 (0.585, 
0.655) 
0.5 14.34 
Unplanned Revision 5981.06 47.81.86 0.260 (15)  0.62 (0.61, 0.62) 0.5 16.36 
Implant Rupture 6948.81 5675.46 0.057 (15,16) (0.076, 0.049) 0.624  0.5 16.36 
Saline 
 
 
 
 
 
 
  
Successful Surgery 6765.52 5468.32 0.446 (17,18) (0.44, 0.454) 0.72 (3) (0.476, 
0.923) 
31.4 15.40 
Complication States 
 
 0.554  
 
 
  
Capsular Contracture 
Grade III/IV 
5946.71 4747.51 0.146 (17,18) (0.127, 0.161) 0.59 (0.58, 0.6) 0.5 15.31 
Explantation 5750.66 4781.86 0.079 (17)  0.61 (0.585, 
0.655) 
0.5 13.90 
Unplanned Revision 5981.06 4551.46 0.226 (17)  0.62 (0.61, 0.62) 0.5 15.33 
Implant Rupture 6461.71 5164.51 0.103 (17,18) (0.099, 0.105) 0.615  0.5 15.33 
1Range refers to highest and lowest reported values for a probability or utility.  2All utilities were generated from a systematic review of published utilities 
(Chapter 2, Table 2.5) except those for successful surgery which were generated from published BREAST-Q data.(3) 3QALYs discounted at 3% per year. 4Utility 
for implant rupture silicone adapted from unplanned revision since rupture is typically asymptomatic. 5Utility for implant rupture saline adapted from 
explantation since deflation results in temporary explantation-like deformity 
 
Chapter 3 
 68 
 
Figure 3.2 Decision model used in cost-utility analysis for saline versus silicone implants in breast reconstruction (SJHC Data).  
Probabilities displayed below branches. Costs and QALYs displayed to the right of terminal branches.
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3.3. Results 
The cost-utility analysis revealed an incremental cost increase of $103.63 associated with 
the use of silicone implants and a gain of 0.89 QALYs. The incremental cost-utility ratio 
was $116.51 per QALY for silicone implants (Table 3.8) . Overall, silicone implants are 
cost-effective as the ICUR was less than the WTP threshold. The analysis was also 
repeated with cost data from London Health Sciences Centre (LHSC) (Appendix 5, 
Appendix 6), a partner organization in HMMS. Despite a slightly lower base cost for 
saline implants at LHSC, silicone implants were still cost-effective within a WTP 
threshold of $50,000/QALY (Table 3.8). Sensitivity analyses were conducted with 
discounting rates of 1.5% and 5%. When discounted at a rate of 1.5%, the ICUR was 
$79.14.  
Table 3.8 Results of Cost-Utility Analysis of Implant Type in Breast Reconstruction 
Strategy Cost  
($) 
Incremental 
Cost ($) 
Effect  
(QALYs) 
Incremental 
Effect 
(QALYs) 
ICUR  
($/QALY) 
3% Discounting Rate 
SJHC 
     
Saline Implant 9250.52 
 
15.25 
  
Silicone Implant 9354.15 103.63 16.14 0.89 116.51 
LHSC 
     
Saline Implant 7451.51 
 
15.25 
  
Silicone Implant 7679.83 228.33 16.14 0.89 256.71 
1.5% Discounting Rate 
SJHC 
     
Saline Implant 9643.18 
 
18.71 
  
Silicone Implant 9728.01 84.83 19.79 1.07 79.14 
5% Discounting Rate 
SJHC 
     
Saline Implant 8815.77 
 
11.99 
  
Silicone Implant 8940.21 124.44 12.70 0.72 173.74 
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One-way sensitivity analysis of SJHC data revealed that silicone implants were cost-
effective at any complication rate associated with saline implants using a WTP threshold 
of $50,000/QALY. Saline implants became more costly and less effective than silicone 
implants at a complication rate of 0.58. (Figure 3.3). The sensitivity analysis was repeated 
for the LHSC data with similar results. Saline implants were more costly and less 
effective than silicone implants at a complication rate of 0.62 (Figure 3.4). One-way 
sensitivity analysis varying the probability of saline implant rupture demonstrated that 
silicone implants were cost-effective at any rate of saline implant rupture (SJHC Data). 
Silicone implants were more effective and less costly when the probability of saline 
implant rupture reached 0.66 (Figure 3.5). One-way sensitivity analysis was also 
performed varying the probability of saline implant capsular contracture. This 
demonstrated that silicone implants were cost-effective at any probability of saline 
capsular contracture within the $50,000/QALY WTP threshold (Figure 3.6). However, 
with increasing probability of capsular contracture, the ICUR for silicone implants 
increased. This was because capsular contracture was a less costly health state compared 
to two of the remaining complication health states (i.e., implant rupture and unplanned 
revision). This sensitivity analysis was repeated varying the rate of silicone implant 
capsular contracture. With increasing probability of capsular contracture, the ICUR for 
silicone implants decreased consistent with the capsular contracture health state being 
less costly than the remaining complication health states as described above. Silicone 
implants were cost-effective at any rate of capsular contracture within a WTP threshold 
of $50,000/QALY (Figure 3.7).
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Figure 3.3 One-way sensitivity analysis varying complication rate of saline implants (SJHC Data). 
 A. Incremental cost of saline and saline implants as a function of saline implant complication rate. B. Incremental effect of saline and 
silicone implants as a function of saline implant complication rate. Up to a saline implant complication rate of 0.58 it is more effective 
but also more costly to use silicone implants. After this it is cheaper and more effective to use silicone implants. 
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Figure 3.4 One-way sensitivity analysis varying complication rate of saline implants (LHSC Data).  
A. Incremental cost of saline and saline implants as a function of saline implant complication rate. B. Incremental effect of saline and 
silicone implants as a function of saline implant complication rate. Up to a saline implant complication rate of 0.62 it is more effective 
but also more costly to use silicone implants. After this it is cheaper and more effective to use silicone implants.
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Figure 3.5 One-way sensitivity analysis varying probability saline implant rupture (SJHC Data).  
A. Incremental cost of saline and saline implants as a function of saline implant rupture rate. B. Incremental effect of saline and 
silicone implants as a function of saline implant rupture rate. Up to a saline implant rupture rate of 0.66 it is more effective but also 
more costly to use silicone implants. After this it is cheaper and more effective to use silicone implants. 
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Figure 3.6 One-way sensitivity analysis varying probability of saline implant capsular contracture (SJHC Data).  
A. Incremental cost of saline and saline implants as a function of saline implant capsular contracture  rate. B. Incremental effect of 
saline and silicone implants as a function of saline implant capsular contracture rate. As saline implant capsular contracture rate 
increases the incremental cost of silicone implants increases and incremental effect decreases. This was because capsular contracture 
was a less costly health state compared to two of the remaining complication health states (i.e., implant rupture and unplanned 
revision). 
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Figure 3.7 One-way sensitivity analysis varying probability of silicone implant capsular contracture (SJHC Data).  
A. Incremental cost of saline and saline implants as a function of silicone implant capsular contracture  rate. B. Incremental effect of 
saline and silicone implants as a function of silicone implant capsular contracture rate. As silicone implant capsular contracture rate 
increases the incremental cost of silicone implants decreases and incremental effect increases. This was because capsular contracture 
was a less costly health state compared to two of the remaining complication health states (i.e., implant rupture and unplanned 
revision). 
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3.4. Discussion 
Breast reconstruction is becoming increasingly common following both therapeutic and 
prophylactic mastectomy and is important to quality of life in the survivorship period. 
Identifying cost-savings is imperative in resource-limited systems. However, more costly 
interventions must be contextualized in terms of their associated quality of life 
improvement.  
 
This cost-utility analysis compares the two most commonly used types of implants in 
North America, saline-filled and silicone gel implants, in the context of breast 
reconstruction. The results suggest that both saline-filled and silicone implants are cost-
effective within a willingness-to-pay threshold of $50,000/QALY. Further, increasing 
saline-filled implant complication rates beyond 0.58 in a one-way sensitivity analysis 
results in silicone implants being less costly and more effective (i.e. dominant strategy). 
 
This model focused on the unilateral, immediate, one-stage implant-based breast 
reconstruction population. Women included in the model were assumed to have early 
stage (I or II) breast cancer as these women are eligible for immediate breast 
reconstruction. Typically, women with more advanced breast cancer (locally advanced or 
metastatic) are not eligible for this form of reconstruction due to higher risk of 
recurrence, anticipated requirement for adjuvant radiation and altered life-expectancy. 
Further, women with early stage breast reconstruction who survive the first three years 
following diagnosis return to life-expectancy of age-matched controls.(11) For this 
reason, the general population life-expectancy was used in this analysis. This analysis 
focused on unilateral reconstruction. Although contralateral prophylactic mastectomy is 
Chapter 3 
 77 
increasing, unilateral mastectomy continues to be more common. Although a lower 
percentage of women undergoing unilateral mastectomy undergo reconstruction (27.4% 
versus 56% bilateral), this still constitutes a greater total number of unilateral 
reconstructions than bilateral reconstructions.(20) Patients undergoing unilateral implant-
based reconstruction are different from those undergoing bilateral reconstructions in that 
patients undergoing contralateral prophylactic mastectomy tend to be younger, of 
Caucasian race, with private insurance coverage and family histories of breast and 
ovarian cancer.(21–23) They are also different in terms of expected outcomes such as 
symmetry and cosmesis which tend to be better with bilateral reconstructions. Because of 
this, the results of this analysis may not be generalizable to the bilateral reconstruction 
population. However, implant filler is not expected to confer a difference in outcomes 
between unilateral and bilateral reconstructions. This analysis also focused on immediate 
reconstruction since more women are opting for immediate reconstruction in both Canada 
and the United States.(20,24)  
 
The perspective used for this analysis was that of the Ministry of Health and Long-Term 
Care (MOHLTC). Costs relevant to the MOHLTC include operating room costs, surgeon 
and anesthetist billing costs, clinic costs and community care costs. Operating room costs 
were obtained through the institutional case costing centre. The “Schedule of Benefits for 
Physician Services under the Health Insurance Act” was used the surgeon, anesthetist and 
radiologist billing codes for both operating room and clinic-related costs.(14) Patients 
who undergo implant-based breast reconstruction often require community care for drains 
for approximately one week. These costs were not included in this analysis and as such 
this constitutes a gap in the costs from the MOHLTC perspective. 
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Health states were defined based on a review of the literature. The most common 
complications associated with implant filler type were used to determine relevant health 
states. Psychological impacts of different implant filler options were assumed to be 
accounted for by the health state utility value. Duration of each health state was an 
approximation based on surgeon practice patterns. Given typical wait times for repeat 
consultation and surgery, these were felt to be conservative estimates. Certain elements of 
the health state definitions, including surgery duration, influenced costs, such as estimates 
of anesthesiology billing since these billing codes are based on time units. 
 
This model used utilities obtained from the literature. Although this analysis focused on 
women undergoing unilateral reconstruction, none of the included utilities specified 
whether utilities were specific to unilateral or bilateral reconstruction. Conversely, the 
majority of utilities reported in the context of implant-based reconstruction examined the 
immediate implant-based reconstruction scenario.(1,25–28) This suggests that the utilities 
used here may prevent the results of this analysis from being extrapolated to delayed 
reconstruction. It is challenging to know how the utilities used would be influenced by 
unilateral or bilateral reconstruction. Bilateral reconstruction is associated with improved 
symmetry compared to unilateral reconstruction. However, the population of individuals 
undergoing bilateral mastectomy and reconstruction may be different from the unilateral 
population in terms of their expectations of post-operative outcomes. Nonetheless, it is 
not expected that implant filler would influence quality of life based on unilateral versus 
bilateral reconstruction. 
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Varying complication rates influence the relative cost-effectiveness of saline and silicone 
implants. This analysis is unfortunately limited by a lack of high-quality data directly 
comparing saline and silicone implants. A recent Cochrane systematic review was 
published on this topic concluding that it was not possible to delineate differences 
between saline and silicone implants based on existing trials.(29) However, the review 
was limited in several ways. Firstly, there are few randomized controlled trials (RCTs) 
directly comparing saline and silicone implants. Secondly, the RCTs that are published 
do not reflect the currently available implants, particularly with regard to the later 
generations of silicone implants. Some of the largest prospective studies of saline and 
silicone implants come from the Core Studies required for FDA approval. The Core 
Studies are industry-funded, prospective, non-randomized studies in which women 
receiving breast implants for augmentation or reconstruction were followed for 10 years. 
Although there are myriad retrospective and prospective cohort studies of women 
undergoing implant-based breast reconstruction, few provide independent analysis of 
complication rates based on implant type.  
 
Costs for this analysis were obtained from multiple sources of secondary data. Estimates 
of direct and indirect costs of implant-based breast reconstruction were obtained through 
the institutional Case-Costing Centre. This Centre does case-costing for QBPs in breast 
reconstruction through micro-costing initiatives which have the potential to provide 
accurate cost estimates of all resources used. These costs were ultimately aggregated to 
provide average costs for patients undergoing implant-based breast reconstruction. Costs 
for individual implant models are confidential and protected under the competitive 
bidding agreements so average prices of saline and silicone implants available through 
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HMMS were used. Although these costs may be lower than catalogue prices, they may be 
a better reflection of implant costs incurred at centres with competitive bidding 
agreements. However, because local costs were used here, this model may not be 
generalizable to institutions without competitive bidding agreements or other provinces 
with different fee structures for physician and procedure billing. 
 
A decision-tree model was used to perform the cost-utility analysis. Other types of 
models, such as Markov models, can account for repeated events in time. Use of a 
Markov model requires probability estimates of successful surgery, complications as well 
as movement between each well and unwell health state. These models have the 
advantage of being able to account for repeated events in time, such as requiring multiple 
revision surgeries or developing multiple complications. Although conceptually it is 
understood that certain events predispose to further complications (e.g., infection leading 
to higher risk of capsular contracture), transition probabilities are not available in the 
current literature. Given the limitations of the literature, the most appropriate model was 
the decision-tree. Deterministic sensitivity analyses were conducted to determine if the 
baseline decision analysis was robust. Varying overall probability of complications in 
addition to probability of implant rupture and capsular contracture demonstrated that 
silicone implants remained cost-effective within a WTP threshold of $50,000/QALY. 
 
There are increasing numbers of cost-utility analyses examining breast reconstruction 
options. Several have compared autologous and implant-based 
reconstruction.(27,28,30,31) Overall, there is evidence to support cost-effectiveness of 
autologous reconstruction. For instance, Matros et al. found DIEP flap reconstruction to 
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be cost-effective relative to implant-based reconstruction with an ICER of 
$11,941/Breast-QALY.(31) Another CUA found both pedicled and free autologous 
reconstruction to be cost-effective within a WTP threshold of $100,000/QALY relative to 
the do-nothing alternative.(27) Interestingly, that study found implant-based 
reconstruction was not cost-effective as all implant-based reconstructive options 
exceeded the WTP threshold. Importantly, marginal changes in utility may influence 
relative cost-effectiveness.(30) Other CUAs have examined adjuncts to surgery and 
surgical materials such as CT angiography and acellular dermal matrix, both of which 
have been found to be cost-effective.(1,32) In terms of timing for reconstructive surgery, 
single-stage, direct-to-implant reconstruction has been found to be cost effective.(26) 
Thus far, no cost-utility analysis has compared saline and silicone implants. This cost-
utility analysis provides important information to physicians, hospitals and policymakers 
when purchasing implants for breast reconstruction. 
 
Overall, silicone implants are cost-effective for implant-based breast reconstruction. 
Given the improved quality of life-associated with silicone implants and only a marginal 
increase in cost, this analysis supports continued use of silicone implants despite higher 
initial cost. 
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4. Chapter 4: General Discussion and Conclusions 
 
Overview 
This chapter reviews the results and implications of the systematic review of health 
state utility values in breast reconstruction (Chapter 2) and the cost-utility analysis 
comparing saline and silicone implants in breast reconstruction (Chapter 3). These 
analyses add to the existing literature on utility measurement and economic analysis 
in breast reconstruction by contextualizing existing health state utility values based 
on methodology and by demonstrating cost-effectiveness of silicone implants in 
implant-based breast reconstruction. 7 
 
4.1. General Discussion 
The purpose of this paper was to analyze the relative cost-effectiveness of saline and 
silicone implants in the immediate breast reconstruction population. The rationale behind 
this study is that the Canadian health care system is facing increasing fiscal limitations in 
the setting of increasing demand for resources related to, among other things, the aging 
population. Due to improvements in treatment and earlier detection, more women are 
diagnosed with breast cancer and transitioning into the survivorship period with breast 
deformities related to lumpectomy and mastectomy. 
 
                                                        
7A portion of the work covered in Chapters 1 and 2 is included here as part of the Integrated Article 
Format. 
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Mastectomy in particular has increased in frequency over the years, and with it the 
demand for post-mastectomy reconstructive surgery. Breast reconstruction does not 
prolong life but is associated with improvement in quality of life for women in the 
survivorship period.(1) Implant-based reconstruction is the most common surgical 
approach.(2) Examining the quality of life changes associated with different approaches 
to implant-based breast reconstruction can help find economic efficiencies as well as 
justify treatments that offer significant improvements in quality of life. 
 
This project was undertaken in two parts. First, a systematic review of the literature was 
conducted to identify health state utility values (HSUVs) published in the breast 
reconstruction literature. Methodological strengths of this review include the use of 
multiple databases, a search strategy developed with librarian assistance and screening 
undertaken by two independent reviewers. Further strengths of this analysis include a 
narrative description of current methodology used to generate HSUVs in breast 
reconstruction. This allows readers to better contextualize existing utilities in breast 
reconstruction, especially when comparing to other illnesses. Specifically, the results 
served to highlight limitations in the existing literature and discrepancies between the 
most common methodology and current guidelines on HSUV generation. Finally, the 
results of the quantitative analysis can serve as a reference for postoperative HSUVs in 
breast reconstruction. This is one of few systematic reviews and meta-analyses on 
HSUVs in breast reconstruction and is unique in its focus on values relating to post-
operative complication health states. 
 
Results of the systematic review demonstrated that the majority of reported utilities were 
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generated in the context of cost-utility analyses, most commonly by surveying medical 
experts (i.e., plastic surgeons) with visual analogue scales (VAS). As discussed in 
Chapter 2, the VAS has some inherent bias.(3,4) Time trade-off (TTO) and standard 
gamble (SG) have greater grounding in economic theory but can be more challenging to 
administer.(3)  
 
Debate exists over whether to survey experts, patients or the general public in health state 
utility evaluation. It is thought that patients become accustomed to states of impaired 
health and, as such, ascribed higher value to those states than healthy individuals would 
ascribe. One study included in the systematic review examined HSUVs related to breast 
reconstruction without nipple reconstruction (i.e., nipple deformity) by surveying the 
general population and medical students.(5) These individuals ascribed a higher utility to 
nipple deformity than experts ascribed to successful implant-based or autologous 
reconstruction in other articles.(6–13) This study evaluated the health state using TTO, 
SG and VAS with the VAS scores being slightly lower, although this difference was not 
statistically significant.(5) This is consistent with estimates derived using the VAS since 
these can be influenced by scaling bias, resulting in values closer to the midpoint than 
with other direct elicitation techniques. Further, they found that higher medical education 
influenced utility scores. Although this study is an isolated example of differences that 
may be related to population surveyed and type of direct valuation technique, it is 
nonetheless important to remember that these factors influence HSUVs when interpreting 
or borrowing from the literature. 
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The systematic review of utilities was large, returning 2249 citations. Although the 
majority could be excluded based on predetermined criteria after a review of title and 
abstract, there were a large number of studies that described quality of life data by patient 
report. Unfortunately, the majority of these studies used ad hoc surveys and non-
preference-based health status measures, preventing this quality of life data from being 
used to generate utilities in our analysis. Further, few studies reported quality of life data 
with respect to complication states. Post-surgical complication states are typically of 
short duration with patients returning to baseline quality of life over a period of weeks to 
months. However, this limits the useful information available to translate into utility 
measures. Finally, there is significant variability in the use of generic and disease-specific 
health status measures. Generic tools, whether preference-based or not, allow for 
comparison across different disease populations.(3) However, these can be insensitive to 
changes in quality of life in surgical patients which may be temporary or based on body 
image, psychosocial and sexual well-being in addition to physical well-being.(14) 
Disease-specific measures tend to be better able to delineate these nuances. However, few 
have passed through rigorous psychometric testing in the breast reconstruction population 
resulting in poor internal and external validity.(14) 
 
The BREAST-Q is a disease-specific, patient-reported outcome measure that was 
developed using the Rasch psychometric method and provides interval level 
measurement.(15) The BREAST-Q has six subscales including satisfaction with breasts, 
satisfaction with outcome, psychosocial well-being, sexual well-being, chest well-being 
and abdominal wall physical well-being. Items are summed for each domain and 
transformed into a score ranging from 0-100. It is becoming more commonly used as a 
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patient-reported quality of life metric in clinical studies and has been used for utility 
generation in two cost-utility analyses.(11,16) Unfortunately, preference-rating has not 
been done for the BREAST-Q. Studies that use utilities derived from BREAST-Q data 
use the average score from the subscales. Utilities based on BREAST-Q scores were 
included in both the quantitative analysis of utilities (Chapter 2) and the cost-utility 
analysis (Chapter 3) since there is reported data on quality of life with saline and silicone 
implants using this measure. Within these limitations these values constitute the best 
quality of life data regarding saline and silicone implants. Because BREAST-Q-derived 
utilities are based on patient opinions, the estimates may be higher than those derived 
from the general population. However, because preference-weighting has not been done 
for the BREAST-Q, scores do not reflect relative importance of each domain and as such 
may not accurately reflect health status. This is a limitation of using BREAST-Q data to 
derive utility estimates. 
 
The results of the systematic review provide information on health state utility values 
relevant to post-surgical health states in breast reconstruction. Although there are several 
limitations to the validity of these HSUVs, until such time that preference weighting and 
mapping functions are available for disease-specific questionnaires, they reflect the best 
available quality of life data for implant-based breast reconstruction. Further, despite 
these limitations, the aggregate data reported here provide a better estimate than each 
individual study and can be used as more accurate estimates of HSUVs in future CUAs. 
 
The second stage of the project involved a cost-utility analysis of saline and silicone 
implants in the context of outpatient, immediate, unilateral implant-based breast 
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reconstruction. Data from this analysis came from multiple sources. Utilities were 
obtained from a review of the literature. Operative costing data was obtained from the 
institutional case costing centre. This centre does micro-costing for Quality-Based 
Procedure (QBP) groups, including reconstructive breast surgery. Micro-costing data is 
used to generate average costs for QBPs which can be subdivided based on Case-Costing 
Initiative (CCI) codes. The average cost for all relevant CCI codes was used as the base 
operative cost. Average costs of saline and silicone implants were obtained from the 
institutional purchasing centre, Healthcare Materials Management Services (HMMS). 
Relevant billing codes were used to estimate surgeon and anesthesia costs.  
 
Micro-costing involves estimation of all resource costs. In this scenario micro-costs have 
been aggregated by CCI codes. Unfortunately, immediate breast reconstruction 
procedures have the potential to be categorized under multiple CCI codes and, as such, a 
broad scope of codes were used in an attempt to capture all relevant procedures. In doing 
this, it is possible that micro-costing data from procedures not strictly immediate, 
implant-based breast reconstruction were included. Further, since immediate breast 
reconstruction by definition occurs during the same operation as the mastectomy, a 
component of the cost estimate accounts for the surgical ablation. Since this base cost 
was used as an estimate of operative costs for subsequent procedures (due to similar 
operating room supplies and duration), this may constitute an over-estimation of 
operative costs for subsequent procedures related to complication states. However, this 
potential overestimation is applied to both saline and silicone arms of the analysis. 
 
Implant costs were obtained from HMMS which is responsible for coordinating 
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competitive bidding agreements with industry suppliers. Costs for individual implants at 
St. Joseph’s Health Care (SJHC), London are protected under confidentiality agreements 
so average costs of saline and silicone implants were used. Use of pricing under 
competitive bidding agreements has the potential to underestimate implant-related costs; 
thus, the results of this cost-utility analysis may not accurately reflect costs at institutions 
without such agreements. Indeed, between London Health Sciences Centre (LHSC) and 
SJHC, there were differences in the average costs of saline and silicone implants 
purchased, mainly related to lower cost of saline implants (Appendix 2). Unfortunately, 
because of the aforementioned confidentiality agreements, implant model type and 
numbers purchased were not available, so it is unknown if the cost discrepancy was 
related to the choice of implant subtype, numbers used or differences in the competitive 
bidding agreements. Overall, cost-savings are expected to be similar for both saline and 
silicone implants; however, small changes in implant cost may influence the degree to 
which silicone implants are considered cost-effective (i.e., through changes in the ICUR).  
 
Health state parameter estimates were obtained from the literature, specifically the 
silicone Core studies and the 10-year post-market approval data for saline-filled implants 
from Mentor and Allergan.(17–20) These are large, population-based, prospective studies 
and provide some of the best quality data on implants and related complications. These 
studies have several limitations including industry-sponsorship and the non-randomized 
study design which are potential sources of bias. Unfortunately, a systematic review of 
the literature on implant-related complications (Chapter 3) revealed that there are few 
randomized-controlled trials and prospective, non-randomized trials directly comparing 
saline and silicone implants. This is consistent with a recent Cochrane Systematic Review 
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on the topic.(21) The few published randomized controlled trials were done on earlier 
generations of implants and likely do not reflect the complication profile of implants in 
use today.(22,23) Nonetheless, the fact that only a few studies were used to develop 
parameter estimates is an inherent limitation of this analysis, which stems from the 
limitations of the available literature. 
 
Cost-utility analyses are becoming more common as stakeholders in healthcare funding 
attempt to provide of high-quality services with limited resources. Several cost-utility 
analyses have been published regarding breast reconstruction options. These include 
comparisons of autologous and alloplastic techniques as well as adjuncts to surgery. 
Within the realm of autologous reconstruction, several studies have found free tissue 
transfer to be cost-effective relative to pedicled techniques. Thoma et al. found that free 
TRAM was cost-effective relative to pedicled TRAM and that DIEP flap reconstruction 
was cost-effective relative to TRAM flap reconstruction.(12,13) Conversely, a cost-utility 
analysis done by Grover et al. found both pedicled and free autologous reconstruction to 
be cost-effective with pedicled options being favoured slightly due to lower costs.(7) This 
same study found implant-based reconstruction was not cost-effective relative to the do-
nothing alternative, as it exceeded a willingness-to-pay threshold of $100,000. However, 
this study was unusual in that they found only small improvements in quality-adjusted 
life years for each type of approach relative to the do-nothing option. Other studies have 
found autologous reconstruction to be cost-effective relative to implant-based 
reconstruction. For instance, Matros et al. performed a cost-utility analysis with utilities 
derived from BREAST-Q data and found that DIEP flap reconstruction was cost-effective 
within a WTP threshold of $50,000, with an incremental cost-effectiveness ratio (ICER) 
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of $11,941/Breast-QALY relative to implant-based reconstruction.(16) However, even 
small differences in utility and cost can result in large changes in the ICUR, as 
demonstrated by a Markov model developed by Preminger et al. in which cost and utility 
of implant-based reconstruction and TRAM flap reconstruction were varied.(24) 
Unfortunately, a significant limitation of that model was that it did not generate health 
state utility values specific to each reconstructive modality and instead assumed a 
baseline utility of 0.7 for both TRAM flap and implant-based reconstruction, which was 
then varied in a sensitivity analysis. Nonetheless, a marginal increase in the utility of 
implant-based reconstruction from 0.7 to 0.704 made implant-based reconstruction cost-
effective within a WTP threshold of $50,000/QALY. 
 
Adjuncts to breast reconstruction have also been demonstrated to be cost-effective, such 
as the use of CT angiography and laser-assisted indocyanine green angiography in 
autologous reconstruction.(6,25) Adjuncts to implant-based reconstruction including 
acellular dermal matrix may be cost-effective. One study demonstrated that acellular 
dermal matrix (ADM) is cost-effective relative to staged expander-implant 
reconstruction; however, another analysis suggested that autologous dermal flaps should 
be used when available since these are significantly less costly than ADM with minimal 
difference in quality of life.(8,9) Finally, direct-to implant reconstruction dominates 
staged expander-implant reconstruction.(10) 
 
There are no previously published cost-utility analyses comparing saline and silicone 
implants in the context of breast reconstruction. Saline implants offer an initial cost-
savings relative to silicone implants amounting to approximately $226.60 at SJHC, 
Chapter 4 
 96 
although this is variable based on hospital and competitive bidding agreements 
(Appendix 2). It can be challenging to justify devices with higher initial costs if quality of 
life is not considered. When such information is taken into consideration, silicone 
implants are cost-effective. Institutional variation in cost does influence the degree to 
which silicone implants are cost-effective, as seen with the change in ICUR between 
LHSC and SJHC data (Table 3.8). It is possible that other institutions may find variable 
incremental cost-effectiveness of silicone implants due to different base price relative to 
the cost of saline implants and other perioperative costs. Ultimately, silicone implants 
provide improved quality of life at a marginal increase in cost relative to saline implants. 
This analysis may be useful to physicians, policy-makers and hospital administrators 
when justifying choice of implant in the context of breast reconstruction.  
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5. Appendices 
Appendix 1. Sample Calculations 
Example: Weighted Average of Utility for Successful Surgery 
 
Table A1. Values for Calculation of Utility of Successful Surgery 
Article Successful Surgery Qualifier Utility (x) Weight (w)1 x*w 
Chatterjee et al. 
2013 
Free Autologous 0.85 10 8.50 
Grover et al. 2013 Alloplastic Two-Stage 0.71 9 6.39 
Alloplastic One-Stage 0.74 9 6.66 
Pedicled Autologous 0.83 9 7.47 
Free Autologous 0.85 9 7.65 
Latissimus Dorsi Flap with Implant 0.74 9 6.66 
Krishnan et al. 
2014 
Immediate Alloplastic Two-Stage with 
ADM 
0.7 5 3.50 
Immediate Alloplastic Two-Stage without 
ADM 
0.66 10 6.60 
Krishnan et al. 
2013 
Immediate Alloplastic One-Stage 0.74 10 7.40 
Krishnan et al. 
2016 
Immediate Alloplastic One-Stage 0.69 15 10.35 
Immediate Alloplastic Two-Stage 0.66 15 9.90 
Razdan et al. 2016 Immediate Alloplastic Two-Stage 0.698 196 136.81 
Delayed Autologous 0.692 76 52.59 
Thoma et al. 2003 Autologous 0.87 33 28.71 
Thoma et al. 2004 Autologous 0.87 32 27.84 
Sum 
  
447 327.03 
Weighted Average Utility  = 327.03/447 0.73 
1Weights are equal to number of individuals surveyed 
 
Worked Example – Weighted Average 
 
!̅#$ = 	
∑ ()#)
*
)+,
∑ #)
*
)+,
	  
 
!̅#$ =
	
0.85∗10+0.71∗9+0.74∗9+0.83∗9+0.85∗9+0.74∗9+0.7∗5+0.66∗10+0.74∗10+0.69∗15+0.66∗15+0.698∗196+0.692∗76+0.87∗33+0.87∗32
10+9+9+9+9+9+5+10+10+15+15+196+76+33+32
  
 
!̅#$ = 	
:;<.=:
>><
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!̅#$ = 	0.73  
 
 
Worked Example – Weighted Standard Deviation 
 
?@#$ = 	
AB
∑ C)D)
E*
)+,
CF
	GH∗!FIJ
2 K
HGL
  
 
Where  IF = ∑ #)
*
)+,
H
	 and !̅#$ = 	
∑ ()#)
*
)+,
∑ #)
*
)+,
 
?@#$ = 	M
N
EO,.PQEROS
ER.S
GLT∗=.<:LULEV
L>
  
?@#$ = 	√0.005  
 
?@#$ = 	0.071  
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Table A1.2 Values for Calculation of Utility of Successful Implant-Based Reconstruction 
Article Health State Qualifier Utility 
(x) 
Weight 
(w)1 
x*w 
Grover et al. 2013 Alloplastic Two-Stage 0.71 9 6.39 
Alloplastic One-Stage 0.74 9 6.66 
Krishnan et al. 
2014 
Immediate Alloplastic Two-Stage with 
ADM 
0.7 5 3.50 
Immediate Alloplastic Two-Stage 
without ADM 
0.66 10 6.60 
Krishnan et al. 
2013 
Immediate Alloplastic One-Stage 0.74 10 7.40 
Krishnan et al. 
2016 
Immediate Alloplastic One-Stage 0.69 15 10.35 
Immediate Alloplastic Two-Stage 0.66 15 9.90 
Razdan et al. 2016 Immediate Alloplastic Two-Stage 0.698 196 136.81 
Sum 
  
269 187.61 
Weighted Utility 
 
 = 187.61/269 0.70 
1Weights are equal to number of individuals surveyed 
 
Table A1.3 Values for Calculation of Utility of Successful Autologous Reconstruction 
Article Health State Qualifier Utility 
(x) 
Weight (w)1 x*w 
Chatterjee et al. 
2013 
Free Autologous 0.85 10 8.50 
Grover et al. 2013 Pedicled Autologous 0.83 9 7.47 
 
Free Autologous 0.85 9 7.65 
Razdan et al. 2016 Delayed Autologous 0.692 76 52.59 
Thoma et al. 2003 Autologous 0.87 33 28.71 
Thoma et al. 2004 Autologous 0.87 32 27.84 
Sum 
  
169 132.76 
Weighted Utility 
 
 = 132.76/169 0.79 
1Weights are equal to number of individuals surveyed 
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Table A1.4 Values for Calculation of Utility of Total Flap Loss 
Article Health State Qualifier Utility 
(x) 
Weight (w)1 x*w 
Chatterjee et al. 
2013 
Free Autologous 0.53 10 5.30 
Grover et al. 2013 Pedicled Autologous 0.58 9 5.22 
 
Free Autologous 0.53 9 4.77 
Thoma et al. 2003 Debridement and Salvage with Tissue 
Expander 
0.61 33 20.13 
 
Debredment 0.44 33 14.52 
Thoma et al. 2004 Autologous 0.61 32 19.52 
Sum 
  
126 69.46 
Weighted Utility 
 
 = 69.46/126 0.55 
1Weights are equal to number of individuals surveyed 
 
 
Table A1.5 Values for Calculation of Utility of Partial Flap Necrosis 
Article Health State Qualifier Utility 
(x) 
Weight (w)1 x*w 
Chatterjee et al. 
2013 
Free Autologous 0.77 10 7.70 
Grover et al. 2013 Pedicled Autologous 0.74 9 6.66 
Free Autologous 0.77 9 6.93 
Thoma et al. 2003 Partial Skin Necrosis 0.71 33 23.43 
 
Fat Necrosis Resolves Spontaneously 0.74 33 24.42 
 
Fat Necrosis w/ Debridement or Drain 0.69 33 22.77 
Thoma et al. 2004 Partial Skin Necrosis 0.71 32 22.72 
 
Fat Necrosis Resolves Spontaneously 0.74 32 23.68 
Sum 
  
191 138.31 
Weighted Utility 
 
 = 138.31/191 0.72 
1Weights are equal to number of individuals surveyed 
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Table A1.6 Values for Calculation of Utility of Mastectomy Skin Necrosis 
Article Health State Qualifier Utility 
(x) 
Weight 
(w)1 
x*w 
Chatterjee et al. 
2013 
Free Autologous 0.7 10 7.00 
Krishnan et al. 
2014 
Immediate Alloplastic Two-Stage with 
ADM 
0.614 5 3.07 
Immediate Alloplastic Two-Stage 
without ADM 
0.6 10 6.00 
Krishnan et al. 
2013 
Immediate Alloplastic One-Stage 0.67 10 6.70 
Thoma et al. 2004 Autologous 0.71 33 23.43 
Sum 
  
68 46.20 
Weighted Utility 
 
 = 46.20/68 0.68 
1Weights are equal to number of individuals surveyed 
 
 
Table A1.7 Values for Calculation of Utility of Hematoma 
Article Health State Qualifier Utility 
(x) 
Weight (w)1 x*w 
Chatterjee et al. 
2013 
Free Autologous 0.77 10 7.70 
Krishnan et al. 
2014 
Immediate Alloplastic Two-Stage with 
ADM 
0.636 5 3.18 
Immediate Alloplastic Two-Stage 
without ADM 
0.61 10 6.10 
Krishnan et al. 
2013 
Immediate Alloplastic One-Stage 0.69 10 6.90 
Krishnan et al. 
2016 
Immediate Alloplastic One-Stage 0.64 15 9.60 
Immediate Alloplastic Two-Stage 0.6356 15 9.53 
Thoma et al. 2003 Drainage Required 0.77 33 25.41 
 
No Drainage 0.79 33 26.07 
Thoma et al. 2004 Autologous 0.77 32 24.64 
Sum 
  
163 119.13 
Weighted Utility 
 
 = 119.13/163 0.73 
1Weights are equal to number of individuals surveyed 
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Table A1.8 Values for Calculation of Utility of Infection 
Article Health State Qualifier Utility 
(x) 
Weight (w)1 x*w 
Chatterjee et al. 
2013 
Free Autologous 0.75 10 7.50 
Grover et al. 2013 Pedicled Autologous 0.72 9 6.48 
 
Free Autologous 0.75 9 6.75 
Krishnan et al. 
2014 
Immediate Alloplastic Two-Stage with 
ADM 
0.605 5 3.03 
Immediate Alloplastic Two-Stage 
without ADM 
0.595 10 5.95 
Krishnan et al. 
2013 
Immediate Alloplastic One-Stage 0.675 10 6.75 
Krishnan et al. 
2016 
Immediate Alloplastic One-Stage 0.5802 15 8.70 
Immediate Alloplastic Two-Stage 0.538 15 8.07 
Thoma et al. 2003 Autologous 0.745 33 24.59 
Sum 
  
116 77.81 
Weighted Utility 
 
 = 77.81/116 0.67 
1Weights are equal to number of individuals surveyed 
 
Table A1.9 Values for Calculation of Utility of Explantation 
Article Health State Qualifier Utility 
(x) 
Weight 
(w)1 
x*w 
Krishnan et al. 
2014 
Immediate Alloplastic Two-Stage with 
ADM 
0.585 5 2.93 
Immediate Alloplastic Two-Stage 
without ADM 
0.585 10 5.85 
Krishnan et al. 
2013 
Immediate Alloplastic One-Stage 0.655 10 6.55 
Sum 
  
25 15.33 
Weighted Utility 
 
 = 15.33/25 0.61 
1Weights are equal to number of individuals surveyed 
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Table A1.10 Values for Calculation of Utility of Capsular Contracture Grade III/IV 
Article Health State Qualifier Utility 
(x) 
Weight 
(w)1 
x*w 
Krishnan et al. 
2014 
Immediate Alloplastic Two-Stage with 
ADM 
0.592 5 2.96 
Immediate Alloplastic Two-Stage 
without ADM 
0.6 10 6.00 
Krishnan et al. 
2016 
Immediate Alloplastic One-Stage 0.59 15 8.85 
 
Immediate Alloplastic Two-Stage 0.58 15 8.70 
Sum 
  
45 26.51 
Weighted Utility 
 
 = 26.51/45 0.59 
1Weights are equal to number of individuals surveyed 
 
 
Table A1.11 Values for Calculation of Utility of Revision 
Article Health State Qualifier Utility 
(x) 
Weight 
(w)1 
x*w 
Krishnan et al. 
2016 
Immediate Alloplastic One-Stage 0.61 15 9.15 
 
Immediate Alloplastic Two-Stage 0.62 15 9.30 
Sum 
  
30 18.45 
Weighted Utility 
 
 = 18.45/30 0.62 
1Weights are equal to number of individuals surveyed 
 
 
Table A1.12 Values for Calculation of Utility of Nipple Deformity 
Article Health State Qualifier Utility 
(x) 
Weight (w)1 x*w 
Ibrahim et al. 2015 VAS 0.84 103 86.52 
 
TTO 0.92 103 94.76 
 
SG 0.92 103 94.76 
Sum 
  
309 276.04 
Weighted Utility 
 
 = 276.04/309 0.89 
1Weights are equal to number of individuals surveyed 
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Table A1.13 Values for Calculation of Utility of Mastectomy Alone 
Article Health State Qualifier Utility 
(x) 
Weight 
(w)1 
x*w 
Grover et al. 2013 
 
0.68 9 6.12 
Razdan et al. 2016 
 
0.586 71 41.61 
Sum 
  
80 47.73 
Weighted Utility 
 
 = 47.73/80 0.60 
1Weights are equal to number of individuals surveyed 
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Appendix 2. Costs Included in Case Costing Centre Procedure Estimate1 
Cost Category Included Components 
Direct Labour Variable Direct Labour 
Variable Direct Other Labour (Contracted-Out) 
Direct Supply Variable Direct Material - General Supplies 
Variable Direct Material - Patient Specific Supplies 
Direct Other Fixed Direct Other - Sundry 
Fixed Direct Labour - Management/Operations 
Fixed Direct Building, Equipment and Grounds - Equipment Expense (including 
amortization), undistributed building and grounds) 
Fixed Direct Labour Administration - Labour Components of the administration 
departments 
Fixed Direct Other - Sundry Administration - Other components of the 
administration department 
Fixed Indirect Variable Indirect - Variable operating expenses from overhead functional centres 
Fixed Indirect - Fixed operating expenses from overhead functional centres 
1Source SJHC Case Costing Centre. 2Labour cost estimated based on cost/min of operating time. 
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Appendix 3. Institutional Implant Costs 
Institution Average Implant Cost ($)1 
 
 
All Implants Saline Implants Silicone Implants Difference 
St. Joseph's 713.82 515 737.6 222.6 
LHSC 640.38 417 736.8 319.8      
Average 666.34 494 737.56 243.56 
1Source HMMS April 2017 - November 2017 
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Appendix 4. SJHC Cost Data 
Health State Silicone 
Successful 
Silicone 
Rupture 
Silicone 
Capsular 
Contracture 
Silicone 
Unplanned 
Revision 
Silicone 
Explantation 
Saline 
Successful 
Saline 
Rupture 
Saline 
Capsular 
Contracture 
Saline 
Unplanned 
Revision 
Saline 
Explantation 
Items 
          
Day Surgery SJHC 6004 6004 5266.4 5266.4 5266.4 5781.4 5781.4 5266.4 5266.4 5266.4 
Procedure R119 350 
    
350 
    
Anesthesia R119 405.27 
    
405.27 
    
Preoperative Consult 81.10 47.95 47.95 47.95 47.95 81.10 47.95 47.95 47.95 47.95 
First Postoperative 
Follow-up Visit 
41.55 41.55 41.55 41.55 41.55 41.55 41.55 41.55 41.55 41.55 
Subsequent 
Postoperative Follow-
up Visit 
106.2 79.65 79.65 79.65 79.65 106.2 79.65 79.65 79.65 79.65 
Procedure Z135 
 
195.95 195.95 
   
195.95 195.95 
  
Anesthesia Z135 
 
315.21 315.21 
   
315.21 315.21 
  
Cost MRI Breast 
 
191.15 
      
0 
 
Procedure R114 
   
230.30 
    
230.30 
 
Anesthesia R114 
   
315.21 
    
315.21 
 
Procedure Z142 
    
150 
    
150 
Anesthesia Z142 
    
165.11 
    
165.11 
MRI Breast Read 
 
73.35 
        
Total State Cost 6988.12 6948.81 5946.71 5981.06 5750.66 6765.52 6461.71 5946.71 5981.06 5750.66 
Total Net Cost 6988.12 13936.93 12934.83 12969.18 12738.78 6765.52 13227.23 12712.23 12746.58 12516.18 
Appendices 
 112 
Total Net Cost 3% 
Discount 
N/A 12158.69 11413.03 11438.59 11267.15 N/A 11573.64 11190.43 11215.99 11044.55 
Total Net Cost 1.5% 
Discount 
N/A 12975.68 12112.21 12141.80 11943.28 N/A 12333.36 11889.61 11919.20 11720.68 
Total Net Cost 5% 
Discount 
N/A 11254.09 10638.88 10659.97 10518.53 N/A 10732.45 10416.28 10437.37 10295.93 
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Appendix 5. LHSC Cost Data 
Health State Silicone 
Successful 
Silicone 
Rupture 
Silicone 
Capsular 
Contracture 
Silicone 
Unplanned 
Revision 
Silicone 
Explantation 
Saline 
Successful 
Saline 
Rupture 
Saline 
Capsular 
Contracture 
Saline 
Unplanned 
Revision 
Saline 
Explantation 
Items 
          
Day Surgery LHSC 4804 4804 4067.2 4067.2 4067.2 4484.2 4484.2 4067.2 4067.2 4067.2 
Procedure R119 350 
    
350 
    
Anesthesia R119 405.27 
    
405.27 
    
Preoperative Consult 81.10 47.95 47.95 47.95 47.95 81.10 47.95 47.95 47.95 47.95 
First Postoperative 
Follow-up Visit 
41.55 41.55 41.55 41.55 41.55 41.55 41.55 41.55 41.55 41.55 
Subsequent Postoperative 
Follow-up Visit 
106.2 79.65 79.65 79.65 79.65 106.2 79.65 79.65 79.65 79.65 
Procedure Z135 
 
195.95 195.95 
   
195.95 195.95 
  
Anesthesia Z135 
 
315.21 315.21 
   
315.21 315.21 
  
Cost MRI Breast 
 
191.15 
      
0 
 
Procedure R114 
   
230.30 
    
230.30 
 
Anesthesia R114 
   
315.21 
    
315.21 
 
Procedure Z142 
    
150 
    
150 
Anesthesia Z142 
    
165.11 
    
165.11 
MRI Breast Read 
 
73.35 
        
Total State Cost 5788.12 5675.46 4747.51 4781.86 4551.46 5468.32 5164.51 4747.51 4781.86 4551.46 
Total Net Cost 5788.12 11463.58 10535.63 10569.98 10339.58 5468.32 10632.83 10215.83 10250.18 10019.78 
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Total Net Cost 3% 
Discount 
 
10011.20 9320.71 9346.27 9174.83 
 
9311.20 9000.91 9026.47 8855.03 
Total Net Cost 1.5% 
Discount 
 
10678.48 9878.89 9908.49 9709.96 
 
9918.41 9559.09 9588.69 9390.16 
Total Net Cost 5% 
Discount 
 
9272.36 8702.68 8723.77 8582.32 
 
8638.88 8382.88 8403.97 8262.52 
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Appendix 6. Decision Tree for LHSC Data 
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